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 ABSTRACT 
 
B chronic lymphocytic leukaemia (B-CLL) is a monoclonal haematopoietic 
disorder with expansion of small lymphocytes of B-cells. B-CLL cells 
accumulate in blood, bone marrow, lymph nodes and spleen, resulting in 
enlargement of these organs and decreased bone marrow function. B-CLL is 
the most common leukaemia, with an annual incidence of 1.8 to 3.0 per 100 
000 population in the United States. It is characterised by the accumulation of 
long-lived monoclonal CD5+ B lymphocytes. In vivo normal B-lymphocytes 
derive growth factors through interactions with T-cells and monocytes. In 
culture however, survival and growth of activated B-cells depends on the 
availability of external factors such as interleukins. 
 
B-CLL cells populations are unable to survive in culture long enough to 
respond to the addition of growth factors. Such factors are important for the 
proliferation and survival of many cell types and in the absence of cytokines, 
these cells die as a result of apoptosis. Chronic lymphocytic leukaemia cells 
are influenced in vitro by a number of exogenously added cytokines that 
include IFN- α, IFN-γ, IL-2, IL-4, IL-10, IL-13, IL-15, TGF- β and TNF- α. 
 
The aim of this study was to investigate the effect of cytokines e.g., IFN, IL-2, 
IL-6, IL7 and IL-10 on the proliferation and survival of B-CLL cells and 
furthermore to compare the induction and reduction of spontaneous and 
induced apoptosis in vitro. 
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 Patients with B-CLL were recruited from three centres. Thirty blood samples 
were collected, separated using Ficoll Hypaque Gradient and purified by 
rosetting with AET treated SRBC.  The proliferation and survival of B-CLL 
cells were studied in vitro in response to GM-CSF, IFN, IL-2, IL-6, IL7 and IL-
10,. The survival and apoptosis of B-CLL cells in cultures with or without 
interleukins and other growth factors were studied under microscopic 
examinations and DNA agarose gel electrophoresis. 
 
It was observed in B-CLL cells cultures that IFN and IL-2 enhanced 
proliferation significantly. IL6, IL-7 and GM-CSF also enhanced proliferation of 
B-CLL cells but not to the greater extent than IL2 and IFN. IL-10 inhibited 
proliferation of B-CLL cells when compared to controls. In a long-term (5-day) 
culture, survival of B-CLL cells was greatly enhanced by IFN and followed by 
IL-2. Therefore it appeared that IFN and IL-2 are the two most potent growth 
factors tested in this study to promote B-CLL cells proliferation and survival. 
The combination of these mitogens did not further enhanced proliferation. IL-6 
and GM-CSF enhanced proliferation and survival of B-CLL cells. IL-7 
promoted proliferation but had no effect on survival of B-CLL cells in-vitro. IL-
10 enhanced apoptosis and did not promote survival of B-CLL cells in-vitro. 
 
IFN and IL2 are survival and promoting growth factors for B-CLL cells in 
culture. In contrast, IL-10 has demonstrated to induce apoptotic cell death of 
B-CLL cells.  
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 In conclusion B-CLL cells proliferated equally well with IFN and IL-2. IL-6, IL-7 
and GM-CSF had a much lower proliferation and survival effect with 
noticeable antiapototic activity when compared to IFN and IL-2. IL-7 was 
found not to promote survival of B-CLL cells and IL-10 enhanced cell death by 
apoptosis. 
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 CHAPTER 1 
 
1  INTRODUCTION 
1.1  B CHRONIC LYMPHOCYTIC LEUKEMIA 
 
B chronic lymphocytic leukaemia (B-CLL) is a monoclonal haematopoietic 
disorder with expansion of small lymphocytes of B-cell lineage. B-CLL cells 
accumulate in blood, bone marrow, lymph nodes and spleen, resulting in 
enlargement of these organs and decreased bone marrow function. B-CLL is 
the most common leukaemia, with an annual incidence of 1.8 to 3.0 per 
100,000 population in the United States. Prevalence is age related, with 5.2 
per 100,000 persons between 35 and 59 years of age and 30.4 per 100,000 
persons between 80 and 84 years of age. It affects twice as many men as 
women and is less common in Japanese and other Asian populations [1 & 2].        
 
B-CLL is the most common leukaemia in the Western world and because 
patients frequently survive for many years [3]. However, 10 to 20% of CLL 
patients carry 11q23 chromosomal deletion and often exhibit a more severe 
disease course [127]. Recently it was found that patients with increased CD38 
expression have poor prognostic features and have short survival [121], B-
CLL is characterised by highly variable clinical course. Some patients die 
within a few months of diagnosis, whereas others survive prolonged periods 
with out requiring therapy [122]. B-CLL has become the prototypical chronic 
B-cell malignancy and its cellular properties have been used extensively to 
explain the cellular properties of normal B-cells.  However, by all analyses, B-
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 CLL is clearly different from other B-cell tumours, and its cells are so 
distinctive that it is an inappropriate model for normal B-cells [3]. 
 
B-CLL is characterised by the accumulation of long-lived monoclonal CD5+ B 
lymphocytes that expressed high levels of Bcl-2 [4 & 5]. In vivo normal B-
lymphocytes derive their growth factors through interactions with T-cells and 
monocytes. In culture however, survival and growth of activated B-cells 
depend on the availability of external factors such as interleukins. These 
factors may act independently or synergistically in enhancing B-cell 
proliferation. In vitro some B-CLL cells may require signals, which are 
provided by more than one cytokine in order to undergo proliferation [6, 7 & 8].  
 
The prognostic assessment of patients with B-CLL should no longer rely 
exclusively on the Binet or Ria stage but include biological and genetic 
markers at the time of diagnosis in order to make a prediction as accurate as 
possible [126].   
 
1.2   THE DISTINCTIVENESS OF B-CLL  
 
There are three major lines of evidence for the distinctiveness of B-CLL 
provided by epidemiology, molecular and cellular biology. Clinical 
investigation also underscores the distinctiveness of B-CLL.  This topic was 
recently reviewed by Caligaris-Cappio and Hamblin [3]. 
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 Firstly, B-CLL is the only blood malignancy, which did not show an increase in 
frequency in atomic bomb survivors. It is also not associated with exposure to 
toxic drugs and chemicals [1 and 3]. 
 
There is some evidence for a genetic susceptibility and there is no evidence 
for retroviral initiation of the disease. There are also families in which siblings 
have the disease and it appears in succeeding generations at an ever-earlier 
age. For B-CLL, it is very rare in the Far East and in Japanese immigrants to 
the United States [1]. In South Africa, the presentation of CLL, as seen in the 
Bloemfontein academic hospitals, is similar to what is seen world-wide [132]. 
 
Secondly, B-CLL is the perfect example of a human malignancy that primarily 
involves defects in the induction of programmed cell death.  Cellular and 
molecular studies have demonstrated that the gene setting of B-CLL cells is 
optimally organized to avoid apoptosis.  The extended cell survival is further 
shielded by kinetic refractoriness to exogenous stimuli such as interaction with 
bone marrow stoma cells, cytokine that include IL-2, IL-4, IL-10, IL-13, IL-15, 
TNF-α, TGF-β, IFN-α, IFN-γ and B-Cell antigen receptor complex (BCR)[9 & 
10]. 
 
Thirdly, patients with B-CLL have an unusually high prevalence of 
autoimmune phenomena.  In most cases, polyclonal auto-antibodies (auto-
Abs) restricted to self-antigens (self-Ags) expressed only by blood cells cause 
autoimmune cytopenias [11].  Paradoxically, patients also develop 
progressive hypogammaglobulinaemia, which deteriorates with advancing 
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 disease and may achieve a severity not seen in other chronic lymphoid 
malignancies [12]. However, it was found in a case report where Mantle Cell 
Lymphoma was presented with aggressive features like p53 over expression, 
marked leukocytosis and leukostasis [130 & 131]. This kind of severity was 
associated with multiple myeloma with non-hyperdiploidy, often associated 
with translocations other than t(11;14) and chromosome 13 deletion [138] 
 
1.3  THE NATURE OF MALIGNANT B CELLS IN B-CLL 
1.3.1 Immunophenotype 
 
Although B-CLL cells express aberrant markers not found on normal 
equivalent cells, as observed in most leukaemia cells, the immunophenotype 
it demonstrates most closely resembles that of lymphocyte follicles.  They 
express most of the membrane antigens present on mature B cells, but their 
distinctive characteristic is the co-expression of CD5 with faint to virtually 
undetectable amounts of monoclonal surface immunoglobulins (sIgs).  These 
slgs are usually sIgM or sIgD and only rarely sIgG or sIgA [3 &13].   
 
The faint slg/CD5 co-expression serves two purposes.  Firstly, it distinguishes 
B-CLL from the small-cell lymphomas in leukaemia phase that mimic B-CLL 
[14].  Secondly, it provides a clue as to the cell of origin in B-CLL.  Such low 
levels of sIgM are seen only in normal B-lymphocytes that have been 
energised by interaction with self-Ag [15].  Furthermore, normal CD5+ B cells, 
which are found at the edge of germinal centres in the mantle zone of 
lymphoid follicles, often produce poly-reaction, low-affinity, natural auto-Abs 
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 [3, 16].  These auto-Abs are encoded by the same pieces (repertoire) of 
unmutated IgV genes that operate in many cases of B-CLL and share the 
same cross-reactive idiotypes, i.e., the 5lpl-encoded idiotype, represented 
most frequently on the surface of malignant B-CLL cells [17]. 
 
These similarities have resulted in the generation of the hypothesis that B-CLL 
is a malignancy of a mantle zone-based subpopulation of anergic self-reactive 
CD5+ B cells that are devoted to the production of poly-reactive natural auto-
Abs [18]. The evidence of auto-reactivity points essentially to 51pl, although 
other auto-specifities need to be authenticated.  Nevertheless, the ability to 
produce these antibodies, which are retained after malignant transformation, 
may well provide a survival advantage for the leukaemia cells, because the 
interaction of monoclonal auto-reactive sIg with their self-Ag has been shown 
to prevent the apoptosis of the malignant cell [19]. 
 
B-CLL and Mantle Cell Lymphoma are mostly CD5 positive. CD5 expression 
can distinguish the B-CLL of the other chronic B-cell malignancies but not 
between B-CLL and mantle cell lymphoma. However, the presence of a strong 
expression of sIg and lack of CD23 in mantle cell lymphoma can distinguish 
mantle cell lymphoma and B-CLL [136 and 137].  
 
A critical analysis of the immunophenotype of the chronic lymphocytic 
leukaemia (CLL) cell has two corollaries.  Firstly, malignant CD5+B cells 
characteristically express markers such as CD23 [20] and the ability to form 
rosettes with mouse erythrocytes [21] and they share with their normal 
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 counterparts the expression of myelomonocytic antigens [22].  The 
implications of these features are unknown.  Secondly, it is not unusual to 
observe CLL cases with cells that are “atypical” on immunophenotypic 
grounds [3].   
 
Recently there are two described major prognostic factors, which are 
immunoglobulin heavy chain variable region (IgVH) mutation status and cell 
membrane expression of CD38 [123 &125].  CD38 expression is associated 
with unmutated IgVH genes, the expression of CD38 may vary during the 
course of the disease and variation in the survival of patients presenting with a 
p53 mutations [124]. The development of newer prognostic factors, such as 
the mutational status of the IgVH genes, cytogenetics, CD38 expression, 
Zeta-associated protein 70 (ZAP-70) and some serum markers, has allowed 
for further discrimination of patients into risk categories [126, 133, 134 &135]. 
In CLL cells, functional impairment of the p53 pathway is detectable by 
western blotting. The type A defect is characterised by baseline p53 over 
expression and is associated with TP53 mutations. Type B defect is 
characterised by impaired Ionizing radiation induced p53 up-regulations and is 
associated with inactivation of the ataxia telangiectasia-mutated (ATM) gene. 
Both abnormalities are strongly associated with adverse clinical outcome 
[127,&128]. 
 
1.3.2 Kinetic Hyporesponsiveness 
 
More than 99% of circulating B-CLL cells are in the Go phase of the cell cycle 
[23].  It is not clear which of the cell characteristics are directly implicated in 
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 the kinetic hyporesponsiveness and which are epiphenomena.  A prominent 
role appears to involve abnormalities of the B-cell antigen receptor complex 
(BCR), because the mitogenic signals that induce the proliferation of normal B 
cells are weak stimuli for B-CLL cells [24]. 
 
The BCR is a multimeric complex formed by the slg and the IgA/IgB 
(CD79a/CD79b) heterodimer that translates the lg engagement into the 
biochemical signals that drive the B-cell response [25].  The extracellular 
domain of CD79b that is normally present on the malignant cell surface in B-
cell lymphomas is absent in most B-CLL patients [26].  Recently it has been 
claimed that the diminished display of BCR on the membrane of B-CLL cells is 
due to the occurrence of somatic mutations, which are predicted to affect 
CD79b expression [27].  An alternative explanation is offered by the detection 
of a truncated form of CD79b that arises by alternative splicing of the CD79b 
gene and lacks exon 3, which encodes the extracellular Ig-like domain in a 
variety of human B cells and B-cell lines [28, 29].  This alternatively spliced 
variant has been detected in all B-CLL cases analysed, thereby suggesting a 
role for the alternative splicing of the CD79b gene in causing the reduced 
expression of BCR on the surface of B-CLL cells [3].   
 
No matter which mechanism is responsible, the low levels of BCR on the 
membrane of B-CLL cells may account for the defective signal transduction 
via the BCR, which correlates with a reduced induction of protein tyrosine 
kinase activity [30] similar to that seen in anergic normal B cells [31].  A 
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 defective Ca²+ response coupled with an altered pattern of protein tyrosine 
phosphorylation has also been observed in several cases [32]. 
 
Other membrane molecules amplify signalling via the BCR and have an 
accessory role in the signal transduction of B cells [33].  An example is CD22, 
which, when stimulated, potentiates the proliferation induced by anti-Ig.  
Although CD22 is present in the cytoplasm of B-CLL cells, it is absent from, or 
only weakly expressed on, the surface.  Other B-cell malignancies express 
CD22 both on the cell surface and within the cytoplasm [34].  Another 
example is CD21, which is also the receptor for the Epstein Barr virus (EBV).  
B-CLL cells express the EBV receptor and have no defect in EBV receptor 
binding activity or in EBV uptake.  Despite this, it is almost impossible to 
immortalize B-CLL cells with EBV [35].  In contrast, workers have used EBV to 
readily immortalize normal CD5+ and CD5- B cells in order to study their Ig 
gene repertoire (pieces) and antibody production more effectively [36]. 
 
1.4  CELL SURVIVAL 
 
The concept that different cytokines may have a proliferative role in B-CLL is 
relatively old, but, to some extent, still controversial. It is possible that some B-
CLL cells populations are unable to survive in culture long enough to respond 
to the growth factors. Such factors are important for the proliferation and 
survival of many cell types and, in the absence of cytokines, these cells die by 
apoptosis. Apoptosis is an active process which is important in haemopoiesis, 
not only in the selection of the T and B-lymphocytes, but also in the 
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 generation of myeloid and erythroid cells. This process is also involved in 
carcinogenesis and is characterised by specific molecular events with 
identifiable morphological and biochemical changes [6]. 
 
1.5  APOPTOSIS 
 
Apoptosis is a tightly regulated form of physiological cell death, which is 
dependent on the expression of cell-intrinsic suicide machinery, which lead to 
homeostasis [4, 37]. Prominent morphological changes include the nucleus 
condensing, cell shrinkage and cleavage of chromosomal DNA at 
internucleosomal sites, resulting in the generation of a characteristic ladder 
pattern of DNA fragments on electrophoresis. Blebbing of the cell surface 
results in the release of membrane-bound apoptotic bodies. 
Phosphatidylserine, which is normally located on the inner face of the plasma 
membrane, becomes exposed on the outer surface and provides a recognition 
signal for engulfment by phagocytes. Thus, apoptosis results in the rapid and 
efficient removal of superfluous or damaged cells [37].   
 
1.6  CYTOKINES 
 
For such an apparently anergic cell, it is surprising that the B-CLL cell 
produces (or at least displays the mRNA for) virtually all cytokines listed 
below.  Interleukin (IL) 1 alpha, IL-1β, IL-6, IL-7, IL-8, IL-10, IL-13, interferon-
gamma (IFN-γ), tumour necrosis factor (TNF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and transforming growth factor beta 1 
(TGF- β1) have all been detected [38, 39].  Their role in the natural history of 
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 B-CLL is still unclear, even if some are responsible for negative autocrine 
circuits.  Although a role for IL-10 has been advocated, there is still conflicting 
data on its precise role [40, 41].  TGF-β [42] and IFN-γ [43] are frequently 
detectable at high levels in patients’ serum.  As a potent inhibitor of 
lymphocyte proliferation, TGF-β has been proposed as an endogenous 
growth inhibitor that might account for the slow progression of malignant 
growth [44].  TGF-β can also induce apoptosis in several cell systems, 
including human B cells [45].  Interestingly, CLL B cells are resistant to the 
apoptotic effects of TGF-β, which variably inhibits CLL B-cell proliferation 
without affecting apoptosis [46].  IFN-γ promotes the survival of leukaemic 
cells by preventing apoptosis [43]. 
 
Other cytokines, including TNF-α [44], soluble CD23 [20] and IL-8 [47] have 
been proposed as autocrine growth promoting candidates.  However, no 
cytokine is unequivocally and consistently able to force the Go blockade of B-
CLL cells [3]. Cytokines may also derive from, and participate in, a reciprocal 
dialogue between B-CLL cells and the interacting T cells.  Chronic 
lymphocytic leukaemia cells are influenced in vitro by a number of 
exogenously added cytokines including IL-2, IL-4, IL-10, IL-13, IL-15, TNF-α, 
TGF-β, IFN-α and IFN-γ.  IL-4 may be related to the increased expression of 
IL-4 receptors by CLL B cells as compared to normal B cells [48]. 
 
Spontaneous apoptosis in culture of B-CLL cells is probably triggered by the 
absence of survival factors that are present in vivo. Candidate survival factors 
that prevent apoptosis of B-CLL cells in vitro are: IL-4, IFN, IL-2, IL-6, IL-8 and 
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 IL-13 while IL-10 and IL-5 induce apoptosis in these cells [4]. The B-CLL/T cell 
discussion is highlighted by the observation that B-CLL cells and T cells share 
a number of functionally relevant molecules and their counter receptors. CD5 
is associated with the BCR, is co-expressed with its natural ligand CD72 and 
is also present on the membrane of T cells.  Likewise, the T cell-associated 
molecule CD27, a member of the TNF receptor family, is co-expressed with its 
natural ligand CD70 on the membrane of malignant B-CLL cells [49]. 
 
1.6.1 Interleukin 2 
 
Interleukin 2 (IL-2) is a glycoprotein of relative molecular mass (Mr) 15000. It 
is released by T lymphocytes on stimulation by antigen or mitogen and 
functions as a T cell growth factor (TCGF) by inducing the proliferation of 
activated T cells [50]. This lymphokine was first identified by its ability to 
promote the long term in vitro proliferation of activated T cells. It also 
promotes the generation and proliferation of cytotoxic T cells, natural killer 
cells and lymphokine activated killer cells [51]. IL-2 was reported to inhibit in 
vitro apoptosis in a large percentage of B-CLL patients and, in another study, 
B-CLL cells seemed to survive better in the presence of IL-2 [6, 52]. 
 
Cells from B-CLL and mantle cell lymphoma (MCL) rarely express the CD95 
antigen. In culture without IL-2, Bosanquet et al [53] determined that CD95 
levels in B-lymphocytes from CLL and MCL could be upregulated by using 
clinically relevant doses of IL-2 CD95 was expressed on dying CD5+ B-
lymphocytes but only on live cells in 2 out of 15 cases. In live cells from two B-
CLL specimens, IL-2 caused up-regulation of CD95 and was associated with 
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 ex vivo drug resistance. Clinically relevant doses of IL-2 had pleiotropic effects 
on CD95 levels in fresh CLL cells. The link between CD95-induction and ex 
vivo drug resistance may point to a clinically resistant subset of CLL patients 
[53].  
 
1.6.2 Interleukin 6 
 
Human Interleukin 6 (IL-6) is a growth factor for murine and human B-cells 
and it has a relative molecular mass of 21000. IL-6 induces the terminal 
maturation of activated B-cells into antibody producing cells. Combination of 
IL-6 and the soluble IL-6 receptor promote liver cell hyperplasia in vivo. IL-6 
modulates the hepatic expression of acute-phase response genes during 
inflammation. Schirmacher et al [54] suggested that after hepatectomy and 
acute liver failure, there might be a significant production of IL-6 and the 
soluble IL-6 receptor from different cells in the remaining liver which could be 
the intrinsic mechanism of the organ to initiate liver regeneration [54]. The 
hepatic acute phase response is induced by IL-6. It has been shown that IL-6 
and IL-3 act synergistically to support the proliferation of haematopoietic stem 
cells, however, IL-6 does not have antiviral activity [55]. IL-6 was originally 
identified as a B-cell differentiation factor [56] and is a pleiotropic cytokine 
which functions, not only in the immune response, but also in inflammation 
and haematopoiesis [56, 57].  
IL-6 has been reported to induce proliferation of B-CLL cells and to enhance 
survival of these cells through inhibition of spontaneous apoptosis [58]. A 
report by Bussing et al [58] did not support theoretical objections of B-CLL 
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 stimulation via induction of IL-6 in vitro [58]. It has been reported that 
endothelial cells inhibit apoptosis of B-cells and that human recombinant IL-6 
dimer inhibits B-CLL apoptosis, whereas human recombinant IL-6 monomers 
do not [59]. Binding and functional competition between IL-6 dimers and 
monomers had similar affinity for the IL-6 receptors and also IL-6 monomers 
inhibited the anti-apoptotic activity of IL-6 dimers. It was suggested that IL-6 
dimers derived from endothelial cells promote the survival of B-CLL cells [59].  
  
1.6.3 Interleukin 7 
 
IL-7 is a stromal cell derived cytokine which, to date, is the only cytokine on 
which the development of B- and T-cell precursors depends. It is essential for 
the differentiation of gamma delta T-cell receptors. Additionally, IL-7 can 
function as a co-factor during myelopoiesis and is also capable of activating 
monocytes/macrophages and natural killer cells (NK). Its receptor is a 
heterodimer of an alpha chain that specifically binds IL-7 and the common 
gamma chain that is also a component of the receptor for IL-2, IL-4, IL-9 and 
IL-15 [60].  
 
Functions of IL-7 in normal lymphocyte development and activation have led 
to the demonstration of the ability of IL-7 to stimulate lymphopoiesis in 
lymphopenic mice, suggesting a possible clinical application for IL-7 in 
accelerating lymphoid reconstitution in lymphopenic patients [60]. IL-7 and its 
receptor complex are essential for the following:-  
(i) Up-regulation of the expression of TdT and IL-7 Receptor alpha  
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 (ii) Initiating the production of cytoplasmic immunoglobulin mu heavy 
chain (cmu). 
(iii) Promoting the formation of a functional pre-B cell Ag (antigen) 
receptor in/on pro-B-cells.  
These key events, in turn, appear to be a prerequisite both for differentiation 
of pro-B cells to pre-B cells and for proliferation of these cell subsets upon 
continued stimulation with IL-7 [61]. IL-7 is involved in protecting lymphoid 
progenitors from a death process that resembles apoptosis. This protection is 
partly mediated by IL-7 induction of Bcl-2 [62]. 
 
IL-7 induces proliferation of relatively mature tumour cells and this effect is not 
restricted to cells of lymphoid lineage [63]. In T-CLL cells, the IL-7 induced 
proliferation is not inhibited by antibodies to IL-2 receptors or the anti-IL-
antibody and, therefore, IL-7 induces the proliferation of peripheral CD8+ T 
cells, as well as its pathological counterpart [64]  
 
1.6.4 Interleukin 10 
 
IL-10 is an immunoregulatory cytokine produced by TH-2 helper cells, B-cells 
as well as monocytes and macrophages. Because it is a potent inhibitor of 
cytokine production by Th-1 helper T cells, it was originally designated 
cytokine synthesis inhibitory factor [65]. It is also known to promote 
proliferation and differentiation of normal human B cells and is a survival 
factor for Epstein Barr virus infected B cells [65, 66, 67]. B cells express the 
IL-10 receptor the functionality of which is demonstrated by activation of STAT 
1 and STAT3 proteins. Binding of IL-10 to its receptors on B-CLL diminishes 
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 hydrocortisone (HC) induced apoptosis and provides cell survival factors for 
B-CLL cells [66]. On the other hand, IL-10 mRNA expression in leukaemic 
cells from patients with B-CLL is strongly associated with low progressive 
disease [68].  
 
IL-10 has recently been found to inhibit CLL B-cell function in vitro by inducing 
apoptosis and down regulating expression of Bcl-2. Tangye et al [25] 
examined the effect of IL-10 on proliferation, RNA synthesis, IgM secretion 
and viability of leukaemic CD5+ B-cells induced by activation with phorbol 
myriststate acetate (PMA) alone, or in combination with anti-Ig. IL-10 reduced 
PMA and PMA/anti Ig induced proliferation and RNA synthesis. Although 
proliferation and RNA synthesis induced by PMA/anti Ig could be enhanced by 
the addition of IL-2, IL-4, IL-13, IFN-gamma or TNF-alpha, the presence of 
these cytokines failed to abrogate the IL-10 mediated inhibition of leukaemic 
CD5+ B-cell activation. In contrast to the effects on proliferation and RNA 
synthesis, IL-10 did not inhibit IgM secretion and had only a minimal effect on 
the viability of activated cells [69]. 
 
It appears that IL-10 inhibits proliferation of leukaemic CD5+ B-cells by a 
mechanism distinct from the induction of apoptosis and may have therapeutic 
benefits in the treatment of B-CLL by preventing expansion of the malignant 
clone [69]. IL-10 has been reported to increase in vitro apoptotic cell numbers 
in stage 0 patients but not in stage I and II and, on the other hand, that it 
inhibits proliferation of leukaemia CD5+ B cells by mechanisms distinct from 
the induction of apoptosis [52, 69]. Fluckiger et al [40] found that IL-10 inhibits 
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 the DNA synthesis and survival of B-CLL cell. The distinctiveness was on 
inhibiting apoptosis [40], may be through inhibition of DNA synthesis. 
 
1.7  OTHER GROWTH FACTORS 
1.7.1 Interferon alpha 2b   
 
Interferons are a complex group of naturally occurring proteins produced by 
eukaryotic cells in response to various stimuli. These proteins have pleiotropic 
biological activity, among which are anti-proliferative, immunomodulatory, 
antiviral and differentiation-inducing effects [1].  
 
IFN-α and IFN-β are acid stable interferons; they bind to the same receptor 
and are produced primarily by leukocytes and fibroblasts respectively [1]. 
Interferon alpha 2b (IFN-α2b) protects B-CLL cells from apoptotic death and 
promotes survival of leukaemic cells by preventing loss of expression of BCL-
2 in vitro [37, 70].  IFN-α2b was used because it was sponsored by Schering-
Plough.    
 
1.7.2 Granulocyte macrophage colony-stimulating factor 
 
Granulocyte macrophage colony-stimulating factor (GM-CSF) is one of a 
family of glycoproteins that have a potent effect on stimulating the proliferation 
and function of haematopoietic cells [71].  
 
GM-CSF is produced by activated T-lymphocytes, B-lymphocytes, endothelial 
cells, mast cells, fibroblasts, macrophages, mesothelial cells and osteoblasts 
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 in response to specific activating agents. The role of GM-CSF in B-cell 
physiology is unclear. Although B cells can respond to GM-CSF, there is 
controversy concerning the extent to which various resting and activated B-
cell types can themselves produce these cytokines and this cytokine therefore 
function in an autocrine fashion. In combination with other known rescue 
factors, autocrine produced GM-CSF may contribute to normal and malignant 
B-cell survival in vivo. GM-CSF protects murine myeloid leukaemia cell lines 
from apoptotic death induced by cytotoxic drugs and has been shown to 
support the growth of B-CLL leukaemic cells in vitro [71, 72]. GM-CSF was 
used because it was available and shown to support growth of B-CLL [71,72 & 
139].   
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 Table: 1.7.1. Effects of cytokines and other growth factors on B-CLL 
cells 
Cytokine Proliferation Survival Apoptosis 
Interleukin 2 YES YES NO 
Interleukin 6 YES YES NO 
Interleukin 7 YES NO NO 
Interleukin 10 NO NO YES 
Interferon Alpha 2b YES YES NO 
GM-CSF YES YES NO 
 
1.8  CYTOGENETICS AND MOLECULAR ABNORMALITIES 
 
B-CLL is regarded as the cytogenetic Cinderella of blood malignancies for two 
reasons:  firstly, the spontaneous mitotic rate of B-CLL cells is extremely low, 
secondly, the standard mitogen used in the 1960s and 1970s was 
phytohaemagglutinin, a T-cell, but not a B-cell, stimulator.  The use of B-cell 
activators such as lipopolysaccharide, EBV and, especially, 12-0-
tetradecanoulphorbal-13-acetate has improved the cytogenetic definition of B-
CLL [73, 74].  Fluorescent in situ hybridisation and molecular studies 
progressively facilitated the detection of genetic abnormalities and even 
recognized microdeletions in morphologically normal chromosomes [10]. 
 
Gradually, information is accumulating on the molecular effects of the 
chromosomal abnormalities [3], which provided a better understanding of B-
CLL cytogenetics. An abnormal karyotype is observed in approximately 50% 
of patients [75 &76]. However, Gozzetti et al used fluorescence in situ 
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 hybridisation (FISH) was able to detect chromosomal abnormalities of 85% in 
patient with B-CLL [140].Chromosomal analysis provides prognosis 
information for overall survival in addition to that supplied by clinical data in 
patients with B-CLL cell [75].  When a normal karyotype is present, 
metaphase may derive from either T cells or the clonal B-cell population itself.  
The most frequent abnormalities are deletions or translocations of 
chromosome arm 13q14, trisomy 12, deletions of p53 at 17p13.3 and 
deletions at chromosome arms 11q23 and 6q.  Approximately half the patients 
with an abnormal karyotype have a single chromosomal abnormality, one 
quarter has two abnormalities and the remainder have a complex pattern [75, 
76]. 
 
Deletions or translocations at 13q are the most common abnormalities in CLL.  
There is no consensus on the suggestion that the breakpoint cluster region A2 
(BCRA2) deletion at 13q12 is involved [77].  However, a detailed molecular 
delineation of a region of 13q14.3 telomeric to RB-1, which is frequently 
deleted, has been published [78]. With the help of molecular tools, a minimally 
deleted region of no more than 10 kilobases has been recognized and, from 
within this region, two candidate tumour suppressor genes, Leu1 and Leu2, 
have been cloned [79].  These genes show little sequence homology to any of 
those previously published genes [3]. 
 
Patients with 13q14 abnormalities characteristically have a benign disease 
that usually manifests as an isolated, stable or only slowly progressive 
lymphocytosis.  The disease is monoclonal but bears none of the other 
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 hallmarks of a malignancy.  In particular, these patients survive as long as 
their age-and sex-matched controls [80]. 
 
In contrast, trisomy 12 is associated with progressive disease and atypical 
cellular morphology [81, 82].  The biological importance of trisomy 12 is still 
poorly understood, although it has been suggested that one or more genes 
may have been duplicated to lead to a more malignant phenotype [3].   
A surprising difference between CLL cells with trisomy 12 and those with 
13q14 deletions, is the finding that trisomy 12 is predominantly associated 
with unmutated VH genes, whereas CLLs with 13q14 deletions show heavy 
somatic mutation [83].  It is unclear whether this points to two different 
diseases, one deriving from a pre-germinal centre cell and the other from a 
postgerminal centre cell, or to a cell so disordered by genetic damage as to be 
unable to differentiate further [3]. 
 
Deletions and translocations at 11q fall into two distinct types.  Although some 
cases of apparent CLL with translocations at 11q13 involving the Bcl-1 gene 
have been reported [84], most workers believe these to be a variant of mantle 
cell lymphoma [85].  Deletions at 11q23 are found in up to 1% of CLLs.  
Patients with these deletions are reported to have B-CLL with extensive lymph 
node involvement and require an aggressive clinical treatment course [86]. 
 
Mutations or deletions of p53 at 17p13.3 have been reported in up to 15% of 
patients with CLL p53 aberrations. They are particularly associated with 
atypical cellular morphology (characteristically with more than 10% 
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 prolymphocytes), advanced disease, a high proliferation rate and shortened 
survival [87], i.e. the development of a high-grade lymphoma (Richter’s 
transformation) from within the clone [89]. 
 
In contrast to follicular lymphoma, the t(14;18) translocation is exceedingly 
rare [90].  Nevertheless, the Bcl-2 gene product is consistently over-
expressed in B-CLL [91].  The mechanism involved in this over-expression is 
unclear, but it may depend on hypomethylation of the gene, which would lead 
to increased transcription [92], or it may be under the influence of apoptosis-
protecting cytokines [3,5].  In vitro data indicate that IL-4 [93], IFN- α and IFN-
γ [43] inhibition of CLL cell apoptosis is accompanied by preservation or even 
up-regulation of the Bcl-2 protein [3]. IL-10 leads to Bcl-2 down-regulation and 
bax up-regulation high Bcl-2 to bax ratios were found to protect against 
apoptosis [4 & 94].  
 
Bcl-2 belongs to a rapidly expanding family of genes that have an interrelated 
role in the control of apoptosis [95].  Bax codes for a protein that is the partner 
for the Bcl-2 protein [96] and counters its repression of apoptosis; Bcl-xL 
synergises with Bcl-2, whereas Bcl-xS inhibits Bcl-2 function. B-CLL cells 
express high levels of Bcl-2, Bcl-xL, and Bax, whereas Bcl-xS is present in 
low to trace amounts in a smaller proportion of cases.  Thus, the pattern of 
expression of Bcl-2 family genes in B-CLL cells favours the suppression of 
apoptosis. In the same vein, B-CLL cells do not express c-myc, a potent 
inducer of apoptosis [3, 5, 94 & 97]. 
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 Bcl-3 translocations t(14;19) (q32.3;q13.2), are even rarer than Bcl-2 
translocations. In 50% of cases, they are found in association with trisomy 12.  
Patients are frequently younger than 40 years old and the disease is often 
rapidly progressive [3].  The Bcl-3 gene encodes a I kappa B-like protein that 
modulates the activity of NF-kappa B transcription factors [98]. 
 
1.9  MALIGNANT B-CELL / MICRO-ENVIRONMENT 
INTERACTIONS 
 
Several observations indicate that the microenvironment might influence the 
natural history of B-CLL [3 & 72]. In vitro data demonstrates that cytokines 
produced by B-CLL cells modulate the environment in which they accumulate 
[48, 94 &141].  A striking predominance of CD4+ helper T cells is observed in 
involved bone marrow (BM) and lymph nodes and reflects a redistribution of 
T-cell subsets reminiscent of that seen in immunoregulatory disorders such as 
rheumatoid arthritis and sarcoidosis [99].  In vitro data indicates that the 
behaviour of B-CLL cells is influenced by T cell-produced cytokines.  The 
CD4+ T cells are intrinsically normal, but their pattern of cytokine secretion is 
modulated by accessory cells. The tumour cells themselves act as the major 
accessory cells in B-CLL [100].  The co-expression of CD27 and CD70 on 
malignant B-cells may modify their accessory cell function and influence their 
ability to activate T cells [49].  Finally, it is reasonable to suppose that binding 
of B-CLL cells to stromal cells and extracellular matrices may account for the 
in vivo patterns of lymphoid infiltration and thus influence clinical presentation 
[3 & 141]. 
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The migration and traffic pattern of lymphocytes is determined by the 
presence on the cell surface of adhesion molecules. The transmembrane 
heterodimers known as integrins play a central role.  Integrins bind to specific 
ligands and have a cytoplasmic domain connected with the microfilament 
bundles of the cytoskeleton [101].  B-CLL cells have an unusual cytoskeletal 
organization that, among lympohemopoeitic cells, is shared only by cells of 
the monocyte-macrophage lineage [102].  They consistently express the β1 
(CD29) β2 (CD18) integrins together with variable amounts of α3 (CD49c), α4 
(CD49d) and α5 (CD49e). Leukocyte function-associated antigen 1(CD) 
1a/CD18) and α4/ α7 are variably expressed [103].  The leukocyte function-
associated antigen 1 ligands and intercellular adhesion molecules (ICAM)-1 
(CD54), ICAM-2 (CD102) and ICAM-3 (CD50), are also present on the 
surface of CLL cells [69].   
 
Interleukin-4 enhances homotypic adhesion of activated CLL cells by 
selectively up-regulating ICAM-1. The L-selection (CD62L) and the “homing 
receptor” CD44 have been detected in a high proportion of cases.  Chronic 
lymphocytic leukaemia cells bind weakly to the surface of non-stimulated 
endothelium [103].  However, the stimulation of endothelium markedly 
increases the expression of vascular cell adhesion molecule 1 (VCAM-1).  In 
this setting, the endothelial binding of CLL cells with VCAM-1 ligand, α4/β1, is 
enhanced [103].  The expression of α4/β1 may also allow the interaction of 
CLL cells with VCAM-1-expressing sites in the bone marrow and secondary 
lymphoid organs [104]. 
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In vitro, malignant CLL cells have been shown to interact with bone marrow 
stromal cells via β1 and β2 integrins .  This binding rescues CLL cells from 
apoptosis [105] and extends their life span.  These data has suggested a 
potential mechanism to explain the in vivo accumulation and survival of 
malignant cells in the bone marrow. They may also account for the discrepant 
behaviour of cells that have a prolonged half-life in vivo but die rapidly of 
apoptosis in vitro.  It should also be noted that in the early nodular phase of 
bone marrow involvement, B-CLL cells are closely associated with follicular 
dendritic cells, which are absent from normal bone marrow (BM) [106].  
According to Caligaris-Cappio et al [3], the relationship between B-CLL and 
follicular dendritic cells warrants further exploration [3]. 
 
1.10 IMMUNE INCOMPETENCE AND AUTO-IMMUNITY 
 
Immune incompetence is a cardinal feature of B-CLL.  It is characterized by a 
progressive profound hypogammaglobulinaemia that eventually develops in 
all patients as well as by an impaired cell-mediated immunity to recall 
antigens.  B-cell chronic lymphocytic leukaemia cells secrete TGF-β, which is 
a potent inhibitor of B-cell proliferation [42], and release high levels of 
circulating IL-2 thus down-regulating T helper function [107].  Furthermore, B-
CLL cells (as do anergic normal B cells) fail to present soluble antigen and 
alloantigen whereas normal, activated B cells are very effective antigen-
presenting cells (APCs) [108,109 &110].  The inability of B-CLL cells (and of 
anergic normal B cells) to properly act as APCs is explained, at least in part, 
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 by the low levels of sIg and the sub-optimal expression of the co-stimulatory 
molecules CD80 and CD86 [110]. 
 
The defective expression of CD79 may be an additional element. It should 
also be considered that CLL CD4+ T cells express CD40 ligand (CD154) 
mRNA but fail to express the molecule on the cell surface after CD3 ligation 
[111]. CD40+ leukaemic cells have been shown to down-modulate CD154 on 
the surface of normal, donor-activated CD4+ T cells, provided that the ratio 
between CD4+ T cells and Leukemic B cells declines below a critical level 
[111]. In a disease characterized by an excess of CD40 leukaemic cells, such 
a receptor-mediated down-modulation of CD154 could interfere with antigen-
specific cognate interaction. The conclusion drawn from all the above data is 
that the accumulating malignant B-cell population per se is obstructing the 
production of normal antibodies and this may lead to progressive immuno-
incompetence [3].  
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CHAPTER 2 
 
2 OBJECTIVES 
 
The aim of this study was in two folds. Firstly, to investigate the effect of 
cytokines IL-2, IL-6, IL-7, IL-10 and growth factor IFN on the proliferation and 
survival of B-CLL cells. Secondly, to compare the effects of these cytokines 
on B-CLL cell induction and reduction of spontaneous and cytokine induced 
apoptosis in vitro. 
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CHAPTER 3 
 
3 MATERIALS AND METHODS 
 
3.1 ISOLATION OF MONOCLONAL CELLS 
 
Blood samples (40ml) were drawn from 30 B-CLL patients from the Chris Hani 
Baragwanath Hospital Haematology Clinic, ward 495 of the Johannesburg 
Hospital Division of Clinical Haematology and Medical Oncology and the 
Medical Oncology Centre of Rosebank over a period of 3 years. Monoclonal 
cells (MNC) from heparinised peripheral blood (PB) samples were transferred 
to 50ml centrifuge tubes.  An equal volume of phosphate buffered saline 
(PBS) (Highveld Biologicals, South Africa) was added and layered on 3ml 
Ficoll Hypaque (Bio-Whittaker, Maryland, USA) for every 10ml of PB and 
PBS.  
 
Ficoll Hypaque with PB and PBS was centrifuged in a refrigerated centrifuge 
(Sorvall Instruments, RC-3B) at room temperature for 30 minutes at 2000rpm. 
The centrifuge was allowed to slow down without braking. The plasma was 
removed and MNC transferred into a clean tube. MNC were washed in a three 
times volume of Hanks Balanced Salt Solution (HBSS) (Highveld Biologicals, 
South Africa) and then centrifuged for 10min at 1300rpm. The supernatant 
was removed and MNC were re-suspended in HBSS. MNC were manually 
counted and the viability was checked by the Trypan Blue Dye Exclusion test. 
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 If MNC viability was more than 90% and these cells were taken for monocyte 
and macrophages depletion. Monocytes and macrophages were depleted 
from MNC using L-leucin methods as described below (Section 3.2).  
 
3.2 DEPLETION OF MONOCYTES / MACROPHAGES FROM 
MONONUCLEAR CELLS USING L-LEUCIN 
 
MNC were incubated in 1mM L-leucin methyl ether (L-L.M.E) (Sigma, USA) 
filter sterilised by 0.22µm Millex filter unit (Millipore, Bedford) in a complete 
serum-free Roswell Park Memorial Institute solution (RPMI) (GIBCO BRL Life 
Technologies, Paisley, Scotland) at a concentration of 5X106 cell/ml for 40min 
at room temperature.  
 
Cells were washed twice with HBSS and suspended in RPMI-10 (10% foetal 
calf serum in Roswell Park Memorial Institute Solution). Cells were checked 
microscopically for contamination.  
 
When no contamination with mononuclear cells found lymphocytes were 
further separated by rosetting with AET treated SRBC. 
 
3.3   ROSETTING WITH AET TREATED SRBC 
 
Fresh sheep red blood cells (SRBC) (NHLS, Laboratory reagent services, 
South African Institute for Medical Research, South Africa) were centrifuged at 
1300rpm and the 8ml 2-amino-ethyl-isothiouronium bromide (AET) (Sigma, 
USA) was added into 2ml packed sheep red blood cells. The mixture was 
incubated for 20min in a 370C water-bath, and then filled with cold PBS to the 
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 top of the 50ml centrifuge tube and centrifuged for 10min at 1300 rpm at 18-
200C. The supernatant was removed and cells were re-suspended in PBS. 
The cells were washed twice with PBS. Forty-eight millilitres (48ml) of RPMI-
10 was added into 2ml of AET-SRSC and stored at 40C for not more than 3 
days. 
 
To separate T and B cells the resetting method with AET treated sheep red 
blood was used. The cells were rosetted twice with AET treated sheep red 
blood cells to get B cells (CD3 or CD14 positive cell were detected). Two 
millilitres (ml) of foetal calf serum (FCS) (Delta Bio products, South Africa) and 
4ml of AET-SRBC were added to 1ml of PBMC and centrifuged for 5min at 
800rpm at 40C. The solution was then incubated in ice for 1hr. Ficoll (~3ml) 
was placed in a centrifuge tube for every seven mls of PBMC/FCS/SRBC at 
ratio of 1:2:4. The mixture was gently re-suspended by tilting the centrifuge 
tube to re-suspend the pellet solid layer over Ficoll and was then centrifuged 
for a further 35min at 2000rpm at 40C. Approximately three quarters (3/4) of 
the upper layer (culture medium) was removed and the intermediate layer 
removed and transferred into a clean centrifuge tube. The tube was filled with 
Hanks Balanced Salt Solution (HBSS) and centrifuged for 10min at 1300rpm 
at 200C. The washing was repeated and the B-CLL cells re-suspended in 
HbSS. T-cells bound to SRBC were discarded.  
 
3.4  PROLIFERATION ASSAY  
 
B-CLL cells were prepared at a concentration of 2X106/ml and were cultured 
with or without pokeweed mitogen (PWM)  (Sigma UK) at a concentration of 
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 8µg/ml on microtitre plates in a total volume of 0.2ml RPMI 1640 culture 
medium supplemented with 0.3g/ml L-glutamine (Glaxo, Greenfold, UK), 
2-mercaptoethanol (5X106/ml Sigma), 10% FCS and penicillin streptomycin 
(100U/ml & 100ug/ml) (Sigma, USA) or Gentamycin 20 to 50 µg/ml (Schering 
Plough, ZA). Recombinant interleukins (ILs) (Boehringer Mannheim, 
Germany) were added at a concentration of 100ug/ml, interferon 2b alpha 
(Schering-Plough ZA) at 5 MIU/ml and granulocyte-macrophage-stimulating 
factor (GM-CSF) at 100ug/ml.  
 
Three wells containing 0.1ml of cells were filled with 0.1ml RPMI to make total 
of 0.2ml per well. These cells were treated with different interleukins (IL-2, IL-
6, IL7, IL10 (Schering-Plough, New Jersey, USA), IFN2b alpha, GM-CSF & 
Pokeweed mitogen) and these growth factors were used as a single agent 
and also in combination. The cells were cultured in triplicate at 370C for 3 to 5 
days in a humidified atmosphere of 5% CO2. Then 20µl of 5mg/ml 
Dimethylthiazolyl-diphenyl-tetrazolium-bromide (MTT) (Sigma, USA) was 
added in 200µl of cells and the cells were incubated for further 1 to 4 hours 
before a solubiliser (dimethyl sulfoxide DMSO) (Sigma USA) was added and 
then incubated again for one hour or overnight. The absorbance was 
measured at 570nm using a Titrek Multiskan MC microtitre plate reader and 
the results were expressed as median counts/culture [6]. 
 
The combinations of cytokines and growth factors used are presented in table 
3.4.1. below. 
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 Table: 3.4.1. Cytokines, growth factors and combinations used in this 
study. 
Cytokines Growth 
Factors 
Combinations of cytokine and growth factors 
used  
IL-2 PWM IL-2 + PWM IL-2 + IL7 IL-2 +IL-10 
IL-6 GM-CSF IL-6 + PWM IL-2 + IL-6 IL-6 + IL-10 
IL-7 IFN IL-7 + PWM INF + PWM IL-7 +IL-10 
IL-10  IL-10 + PWM GM-CSF+PWM IL-6 + IL-7 
 
These combinations were taken at random to test for the proliferation effect 
since no combinations had been tested before except in case of IL-10 where it 
was compared to IL-2, IL-4 and IFN [40].  
 
Background (i.e. medium) was subtracted from the results. The absorbance 
reading of the culture medium was subtracted from all absorbance readings of 
the cells and controls tested. The results with background are presented in 
appendix I.  
 
These results were expressed in medians and standard deviation was 
calculated and recorded in table: 4.1.1.  
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3.5  EFFECT OF CYTOKINES ON CELL SURVIVAL 
 
Twenty six (26) blood samples of the 30 blood samples collected were used 
for survival tests and the other four samples the volume drawn was not 
enough to be used for the survival tests.  
 
B-CLL cells were prepared at a concentration of 1 to 2 X 10 6 cells/ml and 
cultured either at 4°C (control) and 37°C (experimental) for five days with and 
without cytokines. These cells were treated with different cytokines (IL-2, IL-6, 
IL7, IL10, IFN, GM-CSF & PWM). 
 
After day 1, day 3 and day 5, two drops of cells were taken  from B-CLL cells 
cultured with cytokines and growth factors. Slides of B-CLL cells were 
prepared for the staining and counting of cells. These slides of B-CLL cells 
were stained with 5µg/ml Acridine Orange (Sigma, USA) for five minutes and 
the stained slides of B-CLL cells were counted using flourescent microscopy. 
 
The total number of stained B-CLL cells and B-CLL cells with visibly 
condensed chromatin (apoptotic) were counted. At least 400 cells were 
counted from different randomly selected fields and the results are resented in 
appendix ii and means results in table: 4.2.1.  
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 B-CLL survival was expressed in percentages. This was calculated from 
number of apoptotic cells versus the number of viable cells.  
 
The survival score was presented as percentage, depending on the survival 
factors observed under the microscope and calculated. Cells with less 
condensed chromatin were expressed with higher percentage score than cells 
with more condensed chromatin. The results are presented in table: 4.2.1. All 
scores were recorded and the median of all patients for a particular cytokine 
or growth factor tested were recorded and presented in figure: 4.2.1.  
Formula used to calculate the % survival of B-CLL cells  
 =  Total No of survived cells X 100 
  Total No of cells counted 
The ANOVA procedure and Bonferroni (Dunn) t Test was used to compare 
the difference in survival between day 1 and day 5 on treatment with different 
mitogens comparing day1 versus day 5. Furthermore, comparing difference in 
survival between day1, day3 and day5 between the mitogens tested in B-CLL 
cells culture. 
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 3.6  DNA EXTRACTION AND AGAROSE GEL 
ELECTROPHORESIS  
 
Cells treated with IL-2, IL-6, IL-7, IL-10, IFN, and GM-CSF with or without 
pokeweed mitogen and cells without cytokines from the culture and the 
controls (cells stored at 4ºC) were transferred into 10ml centrifuge tubes, 
washed with PBS, and centrifuged at 2300rpm at 4°C. The supernatant was 
discarded and 3ml of Tris-EDTA buffer (20mM Tris; 5mM EDTA, pH 8.0 
(T20E5)) (Sigma, USA), 200µl 10% sodium dodecyl sulphate (SDS) (Sigma, 
USA) and 500µl of 2mg/ml proteinase K (Promega, Madison, WI USA) was 
added and mixed in each centrifuge tube containing cells. The mixtures were 
incubated at 42-50°C in a water-bath overnight. Approximately 1ml of 
saturated sodium chloride (NaCl) (SAARCHEM, ZA) was added to each tube, 
mixed well and placed on ice for 5min.  
 
The tubes were then centrifuged at 2300rpm for 30min and the supernatant 
decanted into a clean centrifuge tube. Twenty ml of absolute ethanol (Merck 
Lab Supplies, ZA) was added to the supernatant at room temperature. DNA 
was usually observed as fine white particles in the mixture. If the DNA threads 
were not visible, the sample was stored at -20°C overnight or at -70°C for 
30min and then re-centrifuged. All DNA samples were centrifuged at 2300rpm 
for 30min and the supernatant was discarded. 
 
Ice cold 70% ethanol was added up to the 10ml mark and the samples 
centrifuged for a further 30min at 2300rpm. The supernatant was decanted 
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 carefully and the DNA pellet left to dry at room temperature. The DNA pellet 
was dissolved in 1ml Tris-borate EDTA (TBE) buffer (Sigma, USA) and placed 
in the incubator at 37°C for 1 to 2 hours to ensure complete dissolution. 
 
The DNA was then analysed on 1.2% agarose gels (BDH Chemicals, 
England) with a 1Kb DNA marker (Promega, Madison, WI USA) 
Electrophoresis was performed in TBE buffer containing 50µl 10mg/ml 
ethidium bromide per litre using a Midi cell Primo EC330 electrophoretic gel 
system (Sigma USA) at a voltage of 100 volts. The gels were photographed 
under ultraviolet illumination. 
 
3.7  STATISTICAL ANALYSIS 
 
The optical density data generated by the B-CLL proliferation assay did not 
meet the assumptions of normality or of equal variances required for 
parametric statistical analysis.  The Kolmogorov-Smirnov two-sample test, a 
nonparametric analogue of the Student two-sample t-test, was therefore used 
to compare the optical densities produced by culture of B-CLL cells in control 
conditions and with different cytokines and growth factors.  ANOVA 
procedure, Bonferroni (Dunn) t test and student t test was used to analyse the 
survival of B-CLL cells at Day 5 treated with different mitogens and to present 
the significance of these differences.  
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CHAPTER 4 
 
4 RESULTS  
 
4.1  PROLIFERATION ASSAY 
  
The effect of adding cytokines to the cultures of B-CLL cells is shown in Table 
4.1.1 and summarized in figure 4.1.1.  The results are expressed in terms of 
absorbance at 570nm, which increases with increased growth. 

 Table: 4.1.1: Proliferation of B-CLL cells in response to cytokines and growth factors, added either individually and in 
combination. Growth of B-CLL cells is expressed as absorbance of the culture at 570nm (see Methods 3.4 section) 
Medians and 95% Confidence Intervals (CI) for each combination are shown at the bottom of each column 
  Control PWM GMCSF 
GMCSF 
+P IFN 
IFN 
+P IL2 
IL2 
+P 
IL2 
+6 
IL2 
+7 
IL2 
+10 IL6 
IL6 
+P 
IL6 
+7 
IL6 
+10 IL7 
IL7 
+P 
IL7 
+10 IL10 
IL10 
+P 
PT 001                     0.370 0.709 0.687 0.703 1.069 0.727 0.726 0.742 0.854 0.657 0.508 0.793 0.780 0.678 0.518 0.723 0.677 0.535 0.494 0.448
PT 002                     0.038 0.131 0.086 0.078 0.181 0.068 0.131 0.117 0.129 0.050 0.028 0.131 0.099 0.149 0.096 0.082 0.072 0.033 0.019 0.015
PT 003                     0.195 0.203 0.303 0.226 0.440 0.230 0.246 0.223 0.226 0.255 0.233 0.303 0.208 0.279 0.221 0.233 0.156 0.137 0.070 0.144
PT 004                     0.193 0.291 0.217 0.181 0.257 0.310 0.290 0.320 0.185 0.259 0.153 0.213 0.277 0.197 0.209 0.261 0.361 0.065 0.126 0.215
PT 005                     0.391 0.423 0.494 0.503 0.661 0.708 0.618 0.725 0.576 0.504 0.652 0.475 0.772 0.462 0.235 0.556 0.562 0.339 0.260 0.354
PT 006                     0.429 0.449 0.298 0.486 0.599 0.599 0.472 0.602 0.429 0.472 0.394 0.595 0.676 0.521 0.397 0.472 0.56 0.404 0.526 0.509
PT 007                     0.557 0.475 0.636 0.436 0.700 0.500 0.607 0.541 0.523 0.580 0.593 0.613 0.571 0.615 0.458 0.505 0.519 0.462 0.357 0.484
PT 008                     0.542 0.484 0.686 0.534 0.742 0.616 0.664 0.589 0.579 0.544 0.556 0.708 0.607 0.647 0.545 0.638 0.591 0.564 0.580 0.525
PT 009                     0.444 0.600 0.637 0.486 0.675 0.612 0.636 0.577 0.543 0.524 0.561 0.511 0.518 0.602 0.436 0.529 0.494 0.403 0.317 0.454
PT 010                     0.470 0.468 0.495 0.493 0.604 0.555 0.601 0.608 0.533 0.551 0.452 0.467 0.561 0.526 0.419 0.469 0.522 0.357 0.373 0.419
PT 011                     0.241 0.223 0.123 0.152 0.268 0.265 0.235 0.260 0.277 0.210 0.233 0.238 0.238 0.276 0.189 0.203 0.267 0.148 0.128 0.205
PT 012                     0.145 0.257 0.354 0.345 0.385 0.273 0.407 0.336 0.298 0.340 0.235 0.341 0.251 0.382 0.192 0.284 0.219 0.155 0.079 0.173
PT 013                     0.139 0.135 0.235 0.182 0.247 0.254 0.275 0.193 0.190 0.167 0.114 0.187 0.105 0.205 0.070 0.191 0.145 0.056 0.091 0.081
PT 014                     0.042 0.161 0.162 0.135 0.206 0.201 0.205 0.189 0.177 0.208 0.047 0.137 0.125 0.170 0.043 0.113 0.151 0.043 0.025 0.033
PT 015                     0.043 0.132 0.198 0.198 0.255 0.266 0.244 0.284 0.177 0.134 0.101 0.147 0.187 0.172 0.030 0.117 0.187 0.014 0.035 0.017
PT 016                     0.046 0.117 0.114 0.164 0.282 0.269 0.222 0.286 0.179 0.218 0.130 0.104 0.228 0.121 0.048 0.123 0.184 0.085 0.051 0.023
PT 017                     0.069 0.099 0.187 0.185 0.150 0.203 0.185 0.218 0.000 0.193 0.067 0.145 0.193 0.169 0.063 0.082 0.139 0.077 0.050 0.065
PT 018                     0.121 0.176 0.152 0.168 0.211 0.187 0.190 0.260 0.152 0.204 0.133 0.113 0.119 0.173 0.120 0.132 0.205 0.095 0.095 0.126
PT 019                     0.275 0.377 0.378 0.308 0.397 0.561 0.553 0.545 0.337 0.357 0.210 0.506 0.473 0.331 0.227 0.423 0.375 0.235 0.182 0.277
PT 020                     0.365 0.426 0.332 0.369 0.503 0.630 0.397 0.660 0.381 0.426 0.118 0.346 0.560 0.337 0.320 0.418 0.408 0.302 0.254 0.359
PT 021                     0.118 0.191 0.130 0.130 0.221 0.198 0.356 0.267 0.193 0.314 0.110 0.271 0.207 0.236 0.196 0.191 0.109 0.192 0.085 0.102
PT 022                     0.181 0.373 0.347 0.212 0.499 0.293 0.320 0.372 0.323 0.353 0.178 0.284 0.305 0.487 0.260 0.320 0.294 0.269 0.146 0.220
PT 023                     0.122 0.370 0.369 0.372 0.454 0.397 0.581 0.490 0.344 0.552 0.246 0.510 0.413 0.367 0.345 0.446 0.265 0.228 0.061 0.072
PT 024                     0.314 0.553 0.501 0.624 0.755 0.688 0.620 0.891 0.556 0.645 0.454 0.520 0.730 0.576 0.214 0.548 0.516 0.330 0.355 0.335
PT 025                     0.113 0.213 0.329 0.320 0.467 0.301 0.468 0.400 0.263 0.376 0.236 0.149 0.259 0.250 0.299 0.163 0.187 0.136 0.032 0.065
PT 026                     0.118 0.200 0.217 0.216 0.251 0.246 0.203 0.284 0.231 0.230 0.223 0.134 0.139 0.260 0.083 0.141 0.194 0.104 0.056 0.206
PT 027                     0.125 0.162 0.193 0.189 0.318 0.361 0.305 0.359 0.246 0.202 0.125 0.204 0.272 0.178 0.189 0.309 0.250 0.091 0.158 0.155
PT 028                     0.042 0.221 0.171 0.237 0.345 0.419 0.358 0.502 0.272 0.341 0.104 0.205 0.239 0.202 0.103 0.213 0.312 0.113 0.017 0.029
PT 029                     0.034 0.069 0.091 0.139 0.149 0.124 0.084 0.244 0.092 0.127 0.042 0.052 0.210 0.088 0.095 0.108 0.167 0.103 0.023 0.031
PT 030                     0.063 0.262 0.296 0.195 0.305 0.335 0.434 0.293 0.209 0.255 0.139 0.191 0.292 0.294 0.205 0.250 0.185 0.170 0.068 0.132
Median                     0.142 0.240 0.297 0.221 0.365 0.306 0.357 0.348 0.268 0.327 0.194 0.254 0.266 0.278 0.207 0.256 0.258 0.151 0.093 0.164
0.039                    0.107 0.101 0.132 0.164 0.152 0.155 0.191 0.108 0.130 0.044 0.108 0.111 0.133 0.045 0.094 0.122 0.037 0.021 0.01995% CI 
0.509                    0.579 0.664 0.584 0.749 0.699 0.651 0.734 0.578 0.616 0.578 0.665 0.753 0.632 0.491 0.601 0.578 0.502 0.511 0.498
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 Figure: 4.1.1: Proliferation of B-CLL cells in response to cytokines and growth factors, added either individually or in 
combination. Growth of B-CLL cells is expressed as Means absorbance of the culture at 570nm (see Methods 3.4 section 
and Table 4.1.1) 
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Table No: 4.1.2: Kolmogorov-Smirnov Two Sample test results of B-CLL, Maximum differences between groups. 
 
                   
              
                  
                 
                 
                   
                  
                   
                   
                  
                 
                 
                   
                   
                   
                   
                   
                   
                   
                   
                   
Control POKE
 
GMCSF
 
GMCSF+P
 
IFN IFN+P IL2 IL2+P IL2+6 IL2+7 IL2+10 
 
IL6 IL6+P IL6+7 IL6+10 IL7 IL7+P IL7+10
 
IL10
  Control 0.000
  POKE     0.367 0.000
  GMCSF   0.367 0.133 0.000
  
GMCSF+P  0.433 0.133 0.133 0.000
  IFN        0.533 0.300 0.267 0.367 0.000
  IFN+P   0.533 0.300 0.233 0.333 0.100 0.000
  IL2  0.500 0.267 0.233 0.300 0.133 0.100 0.000
  IL2+P  0.533 0.367 0.333 0.400 0.133 0.133 0.133 0.000
  IL2+6  0.433 0.167 0.133 0.133 0.267 0.233 0.233 0.267 0.000
  IL2+7  0.467 0.200 0.200 0.267 0.200 0.200 0.200 0.270 0.167 0.000
  IL2+10  0.133 0.267 0.267 0.333 0.533 0.500 0.433 0.533 0.333 0.367 0.000
  IL6  0.367 0.170 0.133 0.167 0.130 0.270 0.267 0.367 0.200 0.230 0.267 0.000
  IL6+P  0.400 0.200 0.167 0.200 0.230 0.200 0.200 0.300 0.167 0.170 0.333 0.200 0.000
  IL6+7  0.467 0.170 0.133 0.167 0.270 0.200 0.200 0.267 0.100 0.130 0.367 0.200 0.130 0.000
  IL6+10  0.233 0.230 0.233 0.300 0.470 0.430 0.400 0.500 0.267 0.300 0.167 0.270 0.300 0.300 0.000
  IL7  0.267 0.100 0.133 0.167 0.300 0.270 0.233 0.333 0.167 0.230 0.267 0.100 0.200 0.200 0.230 0.000
  IL7+P  0.433 0.167 0.133 0.133 0.333 0.300 0.267 0.333 0.100 0.230 0.333 0.170 0.200 0.130 0.270 0.170 0.000
  IL7+10  0.100 0.330 0.333 0.367 0.500 0.500 0.500 0.533 0.433 0.470 0.200 0.330 0.400 0.430 0.230 0.300 0.400 0.000
  IL10   0.267 0.500 0.467 0.567 0.622 0.633 0.633 0.667 0.533 0.567 0.400 0.500 0.533 0.567 0.367 0.467 0.533 0.267 0.000
  IL10+P  0.189 0.300 0.322 0.367 0.500 0.467 0.467 0.533 0.400 0.400 0.200 0.333 0.367 0.400 0.200 0.322 0.367 0.133 0.200
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Contr
ol PWM GMCSF
GMCSF+
P IFN IFN+P IL2 IL2+P IL2+6 IL2+7 IL2+10 IL6 IL6+P IL6+7 IL6+10 IL7 IL7+P IL7+10 IL10
Control 0   
POKE 0.026 0   
GMCSF 0.026  0.921 0  
GMCSF+
P 0.004 0.921 0.921 0  
IFN 0.000 0.108 0.197 0.026  
IFN+P 0.000 0.108 0.334 0.055 0.995 0   
IL2 0.001 0.197 0.334 0.108 0.921 0.995 0   
IL2+P 0.000 0.026 0.055 0.011 0.921 0.921 0.921 0  
IL2+6 0.004 0.740 0.921 0.921 0.197 0.334 0.334 0.197 0  
IL2+7 0.002 0.522 0.522 0.197 0.522 0.552 0.522 0.197 0.740 0  
IL2+10 0.921 0.197 0.197 0.055 0.000 0.001 0.004 0.000 0.055 0.026 0   
IL6 0.026 0.740 0.921 0.740 0.055 0.197 0.197 0.026 0.522 0.334 0.197 0  
IL6+P 0.011 0.522 0.740 0.522 0.334 0.522 0.522 0.108 0.740 0.740 0.055 0.522 0
IL6+7 0.002 0.740 0.921 0.740 0.197 0.522 0.522 0.197 0.995 0.921 0.026 0.522 0.921 0
IL6+10 0.334 0.334 0.334 0.108 0.002 0.004 0.011 0.001 0.197 0.108 0.740 0.197 0.108 0.108 0  
IL7 0.197 0.995 0.921 0.740 0.108 0.197 0.334 0.055 0.740 0.334 0.197 0.995 0.522 0.522 0.334 0  
IL7+P 0.004 0.740 0.921 0.921 0.055 0.108 0.197 0.055 0.995 0.334 0.055 0.740 0.522 0.921 0.197 0.740 0  
IL7+10 0.995 0.055 0.055 0.026 0.001 0.001 0.001 0.000 0.004 0.002 0.522 0.055 0.011 0.004 0.108 0.108 0.011 0
IL10 0.197 0.001 0.004 0.000 0.000 0.000
2.32E-
06  0.000 0.000 0.000 0.011 0.001 0.000 0.000 0.026 0.002 0.000 0.197 0
IL10+P 0.593 0.108 0.069 0.026 0.001 0.002 0.002 0.000 0.011 0.011 0.522 0.055 0.026 0.011 0.522 0.069 0.026 0.921 0.522
 
Table No: 4.1.3: Kolmogorov-Smirnov two-sided probability results for B-CLL cells proliferation assay in response to 
cytokines and growth factors. The significant ones are in bold. 
 
  
The addition of GM-CSF, IL-2, IL-6, IL-7, INF and PWM individually to cultures 
of B-CLL cells all showed significant increase in proliferation when compared 
with negative control cultures (Figure 4.1.1; Tables 4.1.2 and 4.1.3).  The 
greatest effect was shown by INF (d=0.533; p<0.001) and IL-2 (d=0.500; 
p>0.01) while PWM and GM-CSF (positive controls) produced the smallest 
increase (d=0.367; p<0.05).   Proliferation in the presence of IL-10 was less 
than that seen in negative control cultures but the difference was not 
significant (d=0.267; p >0.1).  The difference between the effect of IL-10 and 
the other individual factors tested was striking (IL-2: d=0.633 p<0.001; PWM: 
d=0.500 p< 0.001). 
 
Incubation with a combination of cytokines produced some interesting results.  
Although incubation with IL-2, IL-6 or IL-7, each on their own, increased 
proliferation significantly, in combination the effect was not enhanced further. 
In fact, growth appeared to be less although the differences were not 
significant (Table 4.1.3; Figure 4.1.1).  However, where IL-10 was included in 
the combination of cytokines, proliferation was suppressed, although this only 
reached significance with the combination of IL-2 and IL-10 (d=0.433; p<0.01).  
In none of the cultures in which IL-10 was included was proliferation better 
than that seen in control cultures (d<0.24; p>0.1).  With the exception of IL-7 
(d=0.197;p>0.1), proliferation with IL-10 in combination with other cytokines 
was still statistically greater than with IL-10 alone (d>0.37; p<0.05).  Similarly, 
the addition poke weed mitogen (PWM) did not enhance proliferation and, 
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 although the levels were lower than when the individual cytokines were used, 
they were not significantly different (d<0.2; p>0.1).   
 
In summary, with the exception of IL-10, all of the factors tested increased 
proliferation when compared to control cultures.  IL-10, however, failed to 
enhance growth and, in combination with the stimulatory factors, appeared to 
inhibit their proliferative effect.  This was particularly striking when IL-10 was 
added to IL-2. 
 
4.2  CELL SURVIVAL  
 
In this study B-CLL survival was expressed as a percentage calculated from 
number of apoptotic cells versus viable cells. Total numbers of 400 cells were 
counted and percentage survival was calculated from number of survived cells 
divided by total number of cells counted and multiplied by 100. A table of the 
results is presented in appendix II. B-cells cultured at 37°C without cytokines 
were considered as negative controls and B-cells cultures at 4°C without 
cytokines and those cultured with GM-CSF were considered as positive 
controls. The ANOVA and Bonferroni (Dunn) t Test statistical procedure was 
used to compare the survival results. 
 
In a four to five day liquid culture, B-CLL cell morphology was observed under 
the fluorescent microscope. The results of these experiments are presented in 
table 4.2.1, figure 4.2.1 and appendix II and III. B-CLL cells treated with IL-2 
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 were analysed and a number of morphological changes were observed. At 
Day 1 B-CLL cells showed survival rate of 72%. At Day 3 the survival rate 
decreased to 62% and morphological apoptotic changes increased. At Day 5, 
the results were slightly less than at day 3 with 58% survival. At day 5, 
survival of cells in IL-2 cultures was significantly better than IL-6, positive 
controls (GM-CSF and PWM), IL-7, controls (negative) and IL-10 (Bonferroni t 
p<0.05) but was significantly less than with INF (Bonferroni t, p <0.05) A 
similar trend was seen at days1 and 3. (Figure 4.2.1 and appendix III) 
B-CLL cells were also experimentally treated using IL-6, with 59% survival 
rate at day 1 and 50% at day 5. Compared to other mitogens at day 5 survival 
of cells cultured with IL-6 was similar to GM-CSF (positive control)  but was 
significantly greater than PWM (positive control), IL-7, controls (negative) and 
IL-10 and less than INF and IL-2 (Bonferroni t, p <0.05). A similar trend was 
seen at days1 and 3. (Figure 4.2.1 and appendix III)  
 
IL-7 treated B-CLL cells, at Day 1 had survival rate of 48%, which dropped to 
40% at Day 3 and 37% at Day 5. The survival at day 5 compared to other B-
CLL cells treated with other mitogens was similar to control and PWM but was 
significantly better than IL-10 (Bonferroni t, p < 0.05). When comparing the 
survival of IL-7 was significantly less than IFN, IL-2, IL-6 and GM-CSF.  
 
B-CLL cells cultured with IFN appeared to survive better than any other 
mitogens tested in this study. At Day 1, B-CLL cell survival is 81% and 
dropped to 73% at Day 3. At Day 5, survival dropped slightly to 67%, which 
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was found to have the highest survival at Day 5 compared to all mitogens and 
controls (Bonferroni t, p <0.05).  
 
In this study morphological apoptotic changes were more prominent in IL-10 
treated cells than all other growth factors and cytokines examined. As 
demonstrated in figure 4.2.1., a significant decrease of viable cell numbers 
was usually detected after Day 3 and Day 5. IL-10 treated B-CLL cells results 
from Day 1, there were significant number of apoptotic changes in the cells 
counted with a survival rate of 38% at day 1,  24% at Day 3 and 14% Day 5. .  
The survival was significantly less than all mitogens and controls tested 
(Bonferroni t, p <0.05).  A similar trend was seen at days1 and 3. (Figure 4.2.1 
and appendix III) 
Table 4.2.1: B-CLL Cell Survival results based on the morphological 
changes. Percentage survival results on addition of IL-2, IL-6, IL-7, IL-10, 
IFN, GM-CSF, PWM and Controls cultured at 37 degrees Celsius and 
cells cultured at 4 degrees. 
 
  Number of S cells Number of A cells Total % of Survival 
  D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
IL-2 286 250 233 114 150 167 400 400 400 72 62 58
IL-6 235 206 198 165 194 202 400 400 400 59 52 50
IL-7 192 159 147 208 241 253 400 400 400 48 40 37
IL-10 153 95 54 247 305 346 400 400 400 38 24 14
IFN 325 290 268 75 110 132 400 400 400 81 73 67
GM-CSF 249 223 190 151 177 210 400 400 400 62 56 47
PWM 199 176 160 201 224 240 400 400 400 50 44 40
CONTROL 206 177 140 194 223 260 400 400 400 51 44 35
Cells  at 4oC 238 229 203 162 171 197 400 400 400 60 57 51
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Percentage survival results on addition of IL-2, IL-6, IL-7, IL-10, IFN, GM-CSF, PWM and Controls cultured at 37 
degrees celcius and cells cultured at 4 degrees. 
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Figure: 4.2.1: B-CLL Cell Survival expressed in percentage 
 4.3  GEL ELECTROPHORESIS  
 
The results of DNA fragmentation in B-CLL cells shown by agarose gel 
electrophoresis are presented in figure: 4.3.1. In these experiments, untreated 
B-CLL cells cultured at 37ºC were used as positive controls and untreated B-
CLL cells cultured at 4ºC were used as negative controls. Experiments were 
done on IL-2, IL-6, IL-7, IL-10, GMCSF and IFN.  All these cells were cultured 
for 4 - 5 days before extraction of DNA took place.  
 
DNA analysis by agarose gel electrophoresis revealed that DNA of the B-CLL 
cells treated with IL-2, IL-6, IL-7, IFN and GM-CSF did not show a typical 
ladder pattern of internucleosomal DNA cleavage and degradation of DNA 
into fragments. Internucleosomal DNA cleavage and degradation of DNA was 
not observed in the negative controls.  
 
Cell necrosis was noted in these experiments. This made the results difficult 
to analyse as the typical DNA ladder pattern of apoptosis could have been 
hidden by necrosis. The only typical ladder patterns observed were with the B-
CLL cells treated with IL-10 and positive controls (B-CLL cells without 
cytokines or growth factors). The ladder pattern of the positive control was not 
as prominent as that of IL-10. B-CLL cells stored at 4ºC (positive controls) did 
not show a typical ladder pattern. The results of DNA fragmentation in B-CLL 
cells shown by agarose gel electrophoresis are presented in figure: 4.3.1. In 
these experiments, untreated B-CLL cells cultured at 37ºC were used as 
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 positive controls and untreated B-CLL cells cultured at 4ºC were used as 
negative controls.
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  Figure No 4.3.1: DNA Assay and Gel electrophoresis of B-CLL cells 
treated with different interleukins and growth factors 
IL-2 = 2, IL-6=6, IL-7=7, IL-10 = 10, Interferon alpha 2b=IN, GM-CSF=G, 
Cells with out cytokines = C, Pokeweed Mitogen = P, M = marker 
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 CHAPTER 5 
 
 
 
The studies included cell cultures with three mitogens (PWM, GM-CSF and 
INF), which have previously been shown to enhance lymphocyte proliferation 
[10,37,70,71,72], as positive controls (Figure 4.1
5 DISCUSSION 
5.1 PROLIFERATION ASSAY 
 
.1).  The inclusion of each of 
ese mitogens in the B-CLL cell cultures resulted in significant enhancement 
of proliferation when compared to control cultures containing no mitogen (p< 
0.05 (PWM and GMCSF); p<0.01 (INF)).  The addition of the non-specific 
mitogen (PWM) to either GMCSF or INF appeared to reduce proliferation 
lightly although not significantly. The enhancement of proliferation using 
It has been well established that a number of interleukins enhance B-CLL cell 
proliferation. This study has shown that IFN and IL-2 are potent enhancers of 
-CLL cell proliferation in culture, probably through inhibition of apoptosis.  
These findings are in agreement with published data [6, 37, 52, 70, 72]. IFN 
was presented differently compared to other positive control mitogens. 
th
s
these combinations was still significantly greater than control cultures 
(p<0.05).  Although there was an apparent gradation of effect (INF > GMCSF 
> PWM) the differences were not significant.   The fact that these mitogens 
had a significant proliferative effect in these experiments indicates that the 
methodology used in the proliferation assays is valid. 
 
B
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 Becau s ults over IL-2. It was not expected 
for IFN to effect (not significant) and interesting to 
ee the difference in efficacy compared to IL-2.  
 
5.1.1 Enhancers of proliferation 
se it it  exceptional proliferation res
 show a better proliferation 
s
 
In contrast, IL-10 promotes apoptosis and inhibits DNA synthesis in B-CLL 
cells, thus inhibiting proliferation [40, 52 & 69].  
Several studies indicated that levels of Bcl-2 and Bax proteins regulate the 
mechanism of proliferation of B-CLL cells and apoptosis. A high level of Bcl-2 
protein leads to both the proliferation of B-CLL cells and inhibition of 
apoptosis. High level of Bax protein leads to apoptosis of B-CLL cells. Thus, 
these effects depend on the ratio of Bcl-2 and Bax proteins [3, 37, 69, 94 & 
112]. The Bcl-2 to Bax ratio in B-CLL cells is up regulated by IFN and IL-2 and 
down regulated by IL-10 [3, 37 & 70]. In this study Bcl and Bax proteins were 
not tested. 
 
5.1.1.1 Interleukin 2 
 
In the studies conducted on the effects of IL-2 on B-CLL cells, IL-2 
demonstrated better proliferation effect on B-CLL cells compared to control 
cultures (p<0.001). The proliferation was similar to that seen with positive 
controls. These findings are in agreement with previously reported 
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 observations [6, 52 & 53]. Mainou-Fowler et al [6] found that B-CLL cell 
proliferated after adding IL-2 (p<0.001)[6] and the magnitude of proliferation 
was comparable to the one in this study. Recent literature has shown that IL-2 
is associated with increase levels of Bcl-2 and that over expression of Bcl-2, 
ommonly found in B-CLL, is believed to protect the cells from apoptosis in 
vitro and in vivo [40].  However, the addition of other cytokines or PWM, each 
of which was shown in this study to enhance proliferation in their own right, 
failed to enhance growth further.  There have been not enough reports 
previously on the effect of such combinations and it is interesting to speculate 
on how these combinations might effect B-CLL cell proliferation in culture.    
 B-CLL cultures, neither enhanced the 
roliferation effect but rather decreased it slightly. Reduction in this 
proliferation effect was not significant. None of the previous investigators 
reported having tried these co ar why the effect was not 
increased when IL-2 was combined with IL-6 or IL-7. It is speculated that they 
c
 
When IL6 and IL7 were added to IL-2
p
mbinations. It is not cle
might be competing for the same receptors and if IL-6 or IL-7 occupied a 
receptor, there will be a reduction in proliferation effect since IL-6 and IL-7 
have less proliferation effect compared to IL-2. Reittie et al [113] found that IL-
6 does inhibit TNF induced DNA synthesis [113] and it may affect efficacy of 
IL-2 by inhibiting the IL-2 induce DNA synthesis.  
 
 The addition of IL-10 to cultures with IL-2 reversed the proliferative effect of 
IL-2 leading to IL-2+10 proliferation results not significantly better than the 
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 controls. However, proliferation in the presence of IL-2+10 was significantly 
greater than the effect of IL-10 alone (p<0.05).  Therefore IL-2 can reverse the 
down regulatory effect of IL-10 on B-CLL cells and these results are supported 
by previous findings [40]. The combination of GM-CSF and IFN were not 
studied since were used as controls.  
 
5.1.1.2  Interleukin 6 
  
IL-10 was added to IL-6 B-CLL cultures, proliferation was reduced 
(Figure 4.1.1). Although this reduction was not significant when compared to 
controls (p>0.3) or to that seen with IL-6 alone (p<0.2), proliferation was 
 
In this study B-CLL cells cultured with IL-6 demonstrated a significant increase 
in proliferative effect when compared to B-CLL cells without any interleukins 
(controls) and was as effective as the mitogens used as positive controls 
(p<0.05).  Although IL-6 appeared to be less potent than the other 
interleukins, the differences were not significant (p>0.1). 
When 
significantly less than the proliferation seen with either IL-2 or INF (p<0.02). 
Proliferation using IL-6+10 was still significantly greater than IL-10 alone 
(p<0.05) suggesting that IL-6 was not able to overcome the effect of IL-10 
completely.  While IL-6 appeared to be less potent than IL-2 in reversing the 
effect of IL-10 (Figure 4.1.1), the differences between proliferation in IL-2+10 
and IL-6+10 cultures was not significant.  
MS Seahloli – MEDC 801 MSC (Med) 20 December 2005 amended 6 June 2006 
Student No 9708297R 
 
Page 66 of 123
  
The findings of this study support previous studies showing that IL-6 induces 
roliferation and enhances survival of B-CLL cells through inhibition of 
spontaneo r, this mechanism is controversial [58]. 
ome authors suggested that IL-6, acting in an autocrine manner, may inhibit 
angye et al [114] suggested that the enhancement of cell viability and 
of 
 
. 
l 
 the 
 
 
 
(controls) and was as effective as the mitogens used as positive controls 
p
us apoptosis [58]. Howeve
S
DNA synthesis but prolong survival of B-CLL cells [113]. IL-6 spontaneously 
increases DNA synthesis but in the presence of high concentration of TNF-
alpha, it inhibits TNF induced DNA synthesis in a dose dependent manner 
[113]. 
 
T
suppression of apoptosis were associated with a delay in down-regulation 
bcl-2 [114]. In the studies reported here, where IL-10 was added to IL-6
cultures, IL10 appears to demonstrate its ability to suppress proliferation
Fayad et al [115] suggested that IL-6 inhibit proliferation but prolongs surviva
of B-CLL cells by suppressing apoptosis [115]. This is in contrast with
findings of this study on proliferation but agrees with the survival of B-CLL
report.  
 
5.1.1.3 Interleukin 7 
In this study B-CLL cells cultured with IL-7 demonstrated a significant increase
in proliferative effect when compared to B-CLL cells without any interleukins 
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 (p>0.05) (Figure 4.1.1).  Although IL-7 appeared to be less potent than 
the difference was not sig
IL-2, 
nificant (p>0.1). 
Although  reduced proliferation to levels 
seen in controls, the reduction was not significant and proliferation in cultures 
 
the addition of PWM did not enhance the proliferation. When IL-2 was added 
to IL-7 culture, it also did not have any additive effect on proliferation and data 
 
In this study Interferon with or without PWM, significantly enhanced 
proliferation and promoted the survival of B-CLL cells. These results 
supported previous reports [37, 40, 60, 117 & 118]. In this study it may be 
 
the addition of IL-10 to IL-7 cultures
with IL-10 alone was still significantly less than with the combination IL-7+10 
(p<0.05).  In this study IL-7 inhibited apoptosis and this support the previous 
data relating to IL-7 which suggested that IL-7 played a role in protecting 
lymphoid progenitors and mature tumour cells [62, 63 & 116].  This protection 
was suggested to be partly mediated by IL-7 induction of Bcl-2 [62]. 
The addition of IL-2 to IL-7 did not have any effect on proliferation of B-CLL 
cultured cells. The addition of IL-10 did not inhibit the effect of IL-7 and also 
previously shown that combination of IL-2, IL-7 and TNF had an additive 
proliferative effect [63].  
5.1.1.4 Interferon alpha 2b 
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 suggested that IFN enhanced proliferation through up regulation of Bcl-2 
proto-oncogene. This assumption is based on the previous proven data  [37, 
0, 94, 11 trated similar proliferation effect as IL-
+P in B-CLL culture. Addition of PWM did not make any significant changes 
Addition of PWM in IFN culture with B-CLL cells did not enhance proliferation 
but did slightly slow down the proliferation effect, but this was not significant. 
The addition of PWM was expected to enhance proliferation. Data on this 
xperiment shows that the effect of IFN and IFN+P is similar. It also had the 
5.1.2 Enhancers of apoptosis 
5.1.2.1 Interleukin 10 
positive controls, proliferation in IL-10 cultures was considerably reduced 
4 8 & 119]. Interferon demons
2
in the proliferation. IFN significantly enhanced proliferation of B-CLL cells 
when compared to IL-10, IL-2+10, GM-CSF, IL-10+P, IL-6+10 and IL-7+10.  
 
e
same effect as IL-2P and IL-2. This further proves that addition of PWM does 
not enhance proliferation of B-CLL when cultured with the interleukins tested 
in this experiment. IFN demonstrated to have a non-significant proliferation 
effect when compared to IL-2+6, GM-CSF, IL-6, and IL-7+P and with IL-6+7, 
IL-6+P and IL-7 was just not significant.    
 
 
 
Although proliferation in IL-10 cultures was less than that seen in controls 
(Figure 4.1.1), the difference did not reach statistical significance (p>0.1). 
However, when compared to cultures with other interleukins and with the 
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 (p<0.01).  This difference was greatest when compared to IL-2 and INF 
cultures (p< 0.0001). 
t difference was seen when IL-
0 was combined with IL-2.  Proliferation was markedly lower than with IL-2 
alone (p< 0.01) and with INF alone (p<0.001).  These results show that IL-10 
has a significant negative effect on proliferation when combined with an 
interleukin, which would generally be expected to enhance proliferation. On 
the other hand, INF and IL-2 inhibited apoptosis induced by IL-10. Addition of 
PWM to IL-10 culture decreased the apoptotic effect of IL-10 but the results 
were not significant (p<0.5). IL-10 significantly inhibited proliferation in B-CLL 
cell culture. The effect was significantly reversed by the addition of IL-2 or IFN 
in the culture and these finding were in agreement with previous findings [40]. 
he IL-10 findings in this study were in accordance with those found in the 
literatu
 
decreased Bcl-2 levels [40]. Bcl-2 expression was found to be down regulated 
 
IL10 had a significant negative proliferative effect when combined with other 
interleukins and reduced proliferation to levels no different from controls 
(p>0.05) (See section 4.1).  The most significan
1
T
re [52 & 69].  
It has previously been demonstrated that IL-10 mediated apoptosis showed 
by IL-10 and up-regulate by IL-2 [94 and 112].  
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 In this study IL-10 promoted apoptosis (see section 4.1). A mechanism to 
explain the phenomenon may be through up regulation of proto-oncogene Bax 
levels and by down regulating expression of proto-oncogene Bcl-2. Levels of 
Bax protein were not measured in this experiment, but up regulation of Bax 
proto-oncogene and down regulation of Bcl-2 by IL-10 have been previously 
proven [94, 40 & 120]. The effect of IL-10 in combination with GM-CSF and 
N were not done.  
 
feration as expected. It 
was thought if you add two cytokines or mitogens that lead to B-CLL cells 
proliferation the proliferation will be enhance. This phenomenon was observed 
 most had the similar 
proliferation effect as IL-7+P, IL2+7, IL2+6, and IFN+P. In another example 
where IL-2 and IL-6 where combined, a change in proliferation effect was 
noticed but again this was not statistically significant (p<0.3 compared to IL-2 
and p<0.5 compared to IL-6). These results support the finding of Marinou-
Fowler et al [6] even though there were different cytokines used. IL-2 was 
combined with IL-4, IL-5 and IL-1 did not enhance proliferation of B-CLL cells 
compared to IL-2 alone [6].  
IF
 
5.1.3 Combined Mitogens 
Combination of different combinations of interleukins was done (see table: 
3.4.1.). Combination of these ILs did not enhance proli
in combinations tested in this study. For example: IL-6 
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 When IL-10 was added to IL-6 B-CLL culture, proliferation was reduced but 
not to statistically significant levels. IFN demonstrated an increased 
proliferation of B-CLL cells greater than that of IL-6, but the effect was also not 
ignificant. The above findings were not expected and unfortunately there was 
no enough published literature to compare the results. 
 
l shrinkage, 
condensation of the nuclear chromatin, fragmentation of the nucleus and 
clearing of the chromosomal DNA in B-CLL cells tested. B-CLL survival is 
 
 Morphological changes were observed when IFN treated B-CLL cells were 
examined under a fluorescent microscope. They appear to survive better than 
with any other growth factor / mitogen used in this study. At day five of cells 
s
 
5.2  EFFECT OF CYTOKINES ON CELL SURVIVAL 
It has been suggested that several cytokines play role in growth of leukaemic 
cells or in prolonging cell survival of B-CLL cells in vitro. These cytokines may 
be produced by the leukaemic cells themselves or cells of the immuno-
competent system [6, 37, 58 & 72]. In this study we tested for B-CLL survival, 
noting prominent morphological changes including cel
expressed in percentage in this study, calculated from number of viable cells 
versus total number of cell counted. B-cells cultured at 37°C without cytokines 
were considered as negative controls and B-cells cultures at 4°C without 
cytokines and those cultured with GM-CSF were considered as positive 
controls.  
MS Seahloli – MEDC 801 MSC (Med) 20 December 2005 amended 6 June 2006 
Student No 9708297R 
 
Page 72 of 123
 treated with IFN survived better than the positive controls. IFN was also 
compared with IL-2 and showed to survive better than IL-2, which was highly 
significant compared to all mitogens used in this study. These results concur 
with previous reports presented in the literature [3, 70, 117 & 118]. A 
cells treated with IL-10 appeared to have the most apoptotic changes 
ompared to all B-CLL cells tested with different mitogens in this study. These 
controls (B-CLL cells cultured at 37°C without cytokine and growth 
ctors) were examined and prominent morphological changes were 
ntrols. In general, IL-2 has proved to enhance survival 
f B-CLL cells in culture and supported the previous findings [3, 52, 40, 53 & 
119].  
significant difference was noted mainly at Day 5. These results show that IFN 
is the one of the best growth factors promoting B-CLL survival.  
  
B-CLL 
c
changes were more prominent at Day 5. These results prove that IL-10 lead to 
a poor survival in B-CLL cells [40, 113 & 120]. In this study some of these 
cells responded to IL-10 effect faster than others. This may be due to the age 
of the B-CLL cells at the time blood was taken or whether the patients had 
been treated before collection of blood samples [40].  
 
Negative 
fa
observed. These morphological changes were less prominent compared to 
that of IL-10 treated cells but were more compared to other mitogens testes.  
B-CLL cells cultured with IL-2 had better survival than negative controls and 
better than positive co
o
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 is suspected that IL-7 also promotes B-CLL cells survival since it promotes 
On the other hand, IL-6 had similar survival compared to positive controls 
(GM-CSF) and better survival compared to IL-7, IL-10 and negative control 
(Bonferroni t, p <0.05). These results showed that IL-6 was not different from 
the positive controls.  
5.3  AGAROSE GEL ELECTROPHORESIS AND DNA 
DEGRADATION 
 
m 
%, 
tokines 
horesis 
entation, characteristic of apoptosis. 
It
B-CLL proliferation by preventing loss of expression of BCL-2 in vitro. 
According to the results of these studies, IL-7 had less survival effect 
compared to positive controls GM-CSF, IL-6, IL-2 and IFN (Bonferroni t, p< 
0.05. Compared to negative controls, IL-7 had similar.  (Bonferroni t, p> 0.05). 
These results showed that IL-7 does not have any effect on the B-CLL cells 
survival. 
 
 
Previous studies have demonstrated that B-CLL cells spontaneously die fro
apoptosis during in vitro culture, although the rate remains low compared to 
the important cell death observed with normal B cells (10% versus 35
respectively) [40, 117 & 120]. In this study the spontaneous apoptosis of B-
CLL cells was found to be enhanced by IL-10 rather than any other cy
or growth factors used. This is indicated by agarose gel electrop
showing internucleosomal DNA fragm
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 Furthermore, DNA electrophoresis revealed that IL-10 enhances apoptosis of 
l 
 
 
with the 
previous literature [40].  
  
 
d IL-2. These results 
confirm that INF, IL-2, IL-6 are B-CLL cells apoptosis inhibitors, and that they 
all prevented spontaneous apoptosis in B-CLL cells treated with these 
cytokines. GM-CSF and L-7 has also demonstrated to be inhibitors of 
spontaneous apoptosis in B-CLL cells.  
 
The above information supports data presented in the literature reviewed [6, 
40, 64, 113, 116 & 117]. However some of the gels were not clear and some 
of the ladder pattern might have been missed due to necrotic masking and/or 
undergraded DNA which was also confirmed by Basil and et al [21].  
 
It was previously proven that conventional ethidium bromide staining of DNA 
may not be sufficiently sensitive to reveal a classic DNA ladder. The method 
cultured B-CLL cells with supported Wickremasinghe et al and Fluckinger et a
findings [37 & 40]. The degradation of the DNA extracted from B-CLL cells
cultured without cytokine (positive control) was significantly less than that
found in the presence IL-10. This observation is in agreement 
There were either no ladder patterns observed with B-CLL cells treated with 
IL-2, IFN, IL-6, GM-CSF, PWM, and IL-7 [4, 6, 40, 62, 117]. There was less 
evidence of DNA degradation observed. This evidence of no degradation was
more prominent with the negative controls and IFN an
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 involving the gentle isolation of genomic DNA with a silica-based resin and 
radiolabeled with taq DNA polymerase,
than that of ethidium bromide staining technique [21].
 the sensitivity was found to be better 
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 CHAPTER 6 
 
 
 Th
of B-C is and, 
in their absence, B-CLL cells in-vitro will die by means of apoptosis. These 
features are consistent with up-regulation of the Bcl-2 proto-oncogene. In 
contrast, IL-10 was demonstrated to induce apoptotic cell death, inhibit 
pro
surviva
regula gs demonstrate the array of IL-
10  
 
The effect of the other stimulatory factors tested is less easy to interpret. 
PW
prolife  of 
PW
did pr
apopto
while IL-6 did. The combination of these cytokines and when added 
individually to IL-2 cultures did not result in any difference in proliferation or 
apoptosis. The mechanism of action of these cytokines is uncertain. 
 
 
6 CONCLUSION 
ese results indicate that IFN and IL-2 promote the survival and proliferation 
LL cells in culture. IFN and IL-2, are potent inhibitors of apoptos
liferation, even in the presence of promoting interleukins, and to reduce 
l of B-CLL cells. It is believed that IL-10 down regulates Bcl-2 and up 
tes Bax proto-oncogenes. These findin
activities and constitute an example of the pro-apoptotic effect of cytokines. 
M and GM-CSF, which were included as positive controls, enhanced 
ration but not to the same extent as IL-2 and INF.  In fact, the addition
M demonstrated no additional effects. IL-6 and IL-7, used alone in culture, 
omote proliferation but appeared to be less potent inhibitors of 
sis. On the other hand, IL-7 did not promote survival of B-CLL cells 
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 Appendix I : Table  8.1. Proliferation assay results of B-CLL cells in response to cytokines and growth factors. Absorbance was measured to express the effect of 
these cytokines and these results are with the background. 
                      
PT 001 C IL10P IL7P IL6P IL2P INP M I I I I IL2,7 POKE IL6,10 IL7,10 I GM I I I Gontrol L10 L7 L6 L2 L2,6 CSFP NTER L6,7 L2,10 MCSF 
A. 1.051 0. 1. 6903 1.32 399 1.425 1.401 0.663 1.001 1.357 1.409 1.388 1.348 1.368 1.157 1.112 1.4 1.33 1.667 1.299 1.157 1.28
B 1 1.305 1.346 2 1 64 649 9 1.4 89 76 7 2 8 4 1.371.47  1.3 0. 1.29 1.4 1.3 1.27 1.362 1.191 1.269 1.6 1.387 1.782 1.36 1.17 1.
Average 1. 1. 31.0255 104 1.333 1.4355 1.398 1.3825 0.656 1.15 1.3785 1.449 1.382 1.3125 1.365 1.174 1.1905 1.51 1.3585 1.7245 1.3335 1635 1.34
PT 002 C IL10P IL7P IL6P IL2P INP M I IL7 IL6 IL2 I POKE IL6,10 IL7,10 I GMCSFP INTER IL6,7 I Gontrol L10 L2,7 L2,6 L2,10 MCSF 
A. 0.189 0.163 0.148 0.222 0.267 0.163 0.158 0.174 0.229 0.25 0.233 0.16 0.253 0.268 0.123 0.309 0.205 0.299 0.276 0.199 0.205
B 0. 0. 50.144 124 0.253 0.233 0.225 0.23 0.1 0.122 0.192 0.269 0.287 0.197 0.266 0.181 0.2 0.207 0.208 0.321 0.28 115 0.22
Average 0.1 50.1665 435 0.2005 0.2275 0.246 0.1965 0.129 0.148 0.2105 0.2595 0.26 0.1785 0.2595 0.2245 0.1615 0.258 0.2065 0.31 0.278 0.157 0.21
PT 003 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF 
A. 
0.
344 0. 9274 0.302 0.349 0.389 0.4 0.155 0.211 0.412 0.41 0.363 0.46 0.409 0.348 0.287 0.351 0.322 0.628 0.423 0.349 0.44
B 0. 60.35 317 0.314 0.37 0.361 0.363 0.149 0.233 0.358 0.499 0.432 0.353 0.3 0.398 0.291 0.405 0.434 0.555 0.439 0.421 0.4
Average 0.347 0.2955 0.308 0.3595 0.375 0.3815 0.152 0.222 0.385 0.4545 0.3975 0.4065 0.3545 0.373 0.289 0.378 0.378 0.5915 0.431 0.385 0.4545
PT 004 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF 
A. 0. 50.341 366 0.452 0.401 0.513 0.461 0.145 0.251 0.393 0.359 0.393 0.441 0.432 0.349 0.197 0.322 0.312 0.433 0.338 0.219 0.34
B 0.322 0.341 0.548 0.43 0.405 0.437 0.133 0.279 0.407 0.344 0.464 0.354 0.428 0.346 0.21 0.325 0.328 0.359 0.334 0.365 0.366
Average 0.3315 0.3535 0.5 0.4155 0.459 0.449 0.139 0.265 0.4 0.3515 0.4285 0.3975 0.43 0.3475 0.2035 0.3235 0.32 0.396 0.336 0.292 0.3555
PT 005 C IL10P IL7P IL6P IL2P INP M I I I I IL2,7 POKE IL6,10 IL7,10 I GM I I I Gontrol L10 L7 L6 L2 L2,6 CSFP NTER L6,7 L2,10 MCSF 
A. 1.011 0 5.937 1.333 1.506 1.351 1.416 0.792 0.911 1.3 1.053 1.322 1.212 1.112 0.864 1.105 1.288 1.151 1.225 1.105 1.307 1.26
B 1.162 1.163 1.182 9 9 92 0.6 1 04 89 06 8 6 1 4 1.42  1.4 1.3 1.00 1.2 1.2 1.3 1.18 1.126 0.998 0.964 1.25 1.247 1.489 1.21 1.389 1.11
Average 1 1. 51.0865 .05 1.2575 1.4675 1.4205 1.404 0.696 0.956 1.252 1.171 1.314 1.2 1.119 0.931 1.0345 1.272 1.199 1.357 1.158 1.348 189
PT 006 C IL10P IL7P IL6P IL2P INP M IL10 I IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GM I IL6,7 IL2,10 Gontrol L7 CSFP NTER MCSF 
A. 1.311 1.402 1.512 1.522 1.578 1.529 0.86 1.448 1.377 1.5 1.396 1.396 1.317 1.238 1.323 1.339 1.401 1.458 1.487 1.39 1.149
B 1. 61.375 445 1.437 1.659 1.455 1.498 0.969 1.432 1.395 1.519 1.376 1.376 1.41 1.385 1.314 1.348 1.399 1.568 1.384 1.227 1.27
Average 1.4 51.343 235 1.4745 1 .5905 1 .5165 1.5135 0.9145 1.44 1.386 1.5095 1.386 1.386 1.3635 1 .3115 1.3185 1.3435 1.4 1.513 1.4355 1.3085 1.212
PT 007 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF 
A. 1.461 1.373 1.387 1.495 1.441 1.446 0.912 1.288 1.412 1.519 1.554 1.515 1.404 1.374 1.381 1.471 1.367 1.479 1.414 1.403 1.46
B 1.478 1.42 1.476 1.472 1.466 1.379 0.914 1.252 1.424 1.532 1.485 1.471 1.371 1.368 1.368 1.401 1.33 1.747 1.641 1.609 1.637
Average 1.4695 1.3965 1.4315 1.4835 1.4535 1.4125 0.913 1.27 1.418 1.5255 1.5195 1.493 1.3875 1.371 1.3745 1.436 1.3485 1.613 1.5275 1.506 1.5485
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Control IL10P IL7P IL6P IL2P INP M PT 008 IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 1.306 1.255 1.375 1.32 1.381 1.414 0.801 1.369 1.427 1.523 1.482 1.324 1.279 1.336 1.361 1.363 1.328 1.447 1.422 1.353 1.443
B 1.364 1.38 0 8 7 3 7 3 3 7 5 81 2 2 57 45 51 1.393 1.48 1.383 1.4 3 0.7 5 1.3 6 1.4 4 1.4 9 1.4 1 1. 5 1.2 5 1.339 1.3 3 1.3 1.3 6 1.6 2 1.4 1.3 1.51
Average 1 2 0 3 7 72 4 9 4 91.335 1.3 8 1.384 1.4 1.382 1.4085 0.793 1.37 5 1.4305 1.5 1 1.4565 1.3 7 1.2 7 1.3375 1.357 1.3 1.327 1.53 5 1.43 5 1.3 9 1.47
PT 009 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 1.251 1.239 1.309 1.324 1.393 1.389 0.818 1.109 1.342 1.321 1.411 1.338 1.446 1.253 1.205 1.336 1.265 1.448 1.371 1.35 1.455
B 1.253 1.28 5 9 4 3 1 7 2 3 66 2 1 4 88 65 1.295 1.329 1.377 1.4 1 0.7 9 1.1 1 1.3 2 1.3 8 1.4 8 1.3 6 1. 7 1.235 1.217 1.3 1.3 3 1.5 9 1. 5 1.3 1.43
Average 1.252 1.262 1.302 1.3265 1.385 1.4 2 4 3 0 51 9 3 0 6 52 0.8085 1.1 5 1.337 1.3195 1.44 5 1.3 2 1.4 8 1.244 1.211 1.3 1.2 4 1.48 5 1.41 5 1.3 9 1.445
PT 010 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 1.39 1.315 1.43 1.433 1.479 1.447 0.859 1.244 1.371 1.393 1.505 1.479 1.314 1.379 1.227 1.443 1.394 1.457 1.486 1.4 1.385
B 1.374 1.34 8 6 2 9 6 2 4 4 1 48 1 7 3 28 97 1.438 1.514 1.561 1.4 8 0.9 6 1.3 6 1.3 1 1.3 5 1.5 1 1.4 7 1.4 6 1.284 1.3 2 1.4 1.4 7 1.5 5 1. 9 1.3 1.42
Average 7 2 8 8 7 1 9 55 1 3 64 71.382 1.331 1.434 1.4735 1.52 1.46 5 0.91 5 1.2 5 1.3 1 1.3 9 1.5 3 1.463 1.38 1.3315 1.26 5 1.44 1.4055 1.5 6 1.4 8 1.3 1.40
PT 011 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.367 0.303 0.319 0.399 0.383 0.44 0.179 0.227 0.369 0.401 0.37 0.345 0.355 0.304 0.288 0.397 0.275 0.42 0.441 0.404 0.275
B 0.399 0.39 7 0 1 2 5 8 5 7 9 44 1 9 9 46 51 0.498 0.361 0.421 0.3 3 0.1 5 0.3 2 0.3 1 0.3 8 0.3 3 0.3 9 0.3 4 0.357 0.2 1 0. 0.3 2 0.3 9 0.3 5 0.3 0.25
Average 4 9 6 5 85 1 7 50.383 0.3 7 0.4085 0.38 0.402 0.4065 0.142 0.26 5 0.345 0.3795 0.37 5 0.3 2 0.3645 0.3305 0.2895 0.41 0.2935 0.4095 0.4 8 0.3 5 0.26
PT 012 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.293 0.331 0.326 0.375 0.494 0.378 0.103 0.219 0.415 0.469 0.539 0.447 0.393 0.338 0.273 0.443 0.473 0.505 0.525 0.308 0.525
B 0.264 0.28 3 6 0 1 7 4 99 8 0 42 8 3 0 28 51 0.379 0.393 0.445 0.4 4 0.1 4 0.2 5 0.4 9 0.4 9 0.5 2 0.4 0.3 7 0.312 0.3 3 0. 0.4 4 0.5 2 0.5 5 0.4 0.4
Average 0 1 7 73 8 15 8 1 68 50.2785 0.3 6 0.3525 0.384 0.4695 0.406 0.1335 0.2 2 0.417 0.4 4 0.5405 0.4 0.39 0.325 0.2 8 0.43 0.47 5 0.5185 0.5 5 0.3 0.487
PT 013 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.253 0.206 0.267 0.25 0.348 0.342 0.145 0.215 0.272 0.318 0.361 0.29 0.296 0.199 0.159 0.322 0.281 0.382 0.345 0.25 0.394
B 0.281 0.21 2 1 2 6 1 4 0 3 2 15 3 6 2 35 23 0.2801 0.216 0.294 0.4 3 0.1 2 0.2 4 0.3 7 0.3 2 0.4 5 0.3 1 0.2 1 0.198 0. 1 0.3 0.3 9 0.3 9 0.3 1 0.2 0.33
Average 2 9 0 5 3 4 85 5 3 25 30.267 0.2095 0.2736 0.233 0.321 0.38 5 0.1285 0.21 5 0.3195 0.315 0.4 3 0.29 5 0.26 5 0.1985 0.18 5 0.31 0.31 0.37 5 0.3 3 0.24 0.36
PT 014 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.206 0.192 0.322 0.315 0.348 0.395 0.162 0.192 0.289 0.313 0.388 0.366 0.312 0.215 0.211 0.299 0.313 0.368 0.369 0.206 0.3
B 0.199 0.19 2 5 7 5 8 4 7 8 9 76 7 6 9 09 54 0.301 0.255 0.351 0.3 8 0.1 9 0.1 9 0.2 7 0.2 1 0.3 3 0.3 1 0.3 1 0.191 0.1 5 0.3 0.2 8 0.3 4 0.2 1 0.2 0.34
Average 7 8 6 0 75 5 7 50.2025 0.193 0.3115 0.285 0.3495 0.3615 0.1605 0.1855 0.2 3 0.297 0.3655 0.36 5 0.34 5 0.203 0.2 3 0.33 0.29 5 0.366 0.33 0.20 5 0.322
PT 015 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.203 0.178 0.333 0.385 0.417 0.395 0.165 0.182 0.259 0.293 0.448 0.271 0.293 0.199 0.144 0.311 0.351 0.423 0.301 0.27 0.32
B 0.199 0.17 5 5 0 9 1 5 1 8 9 58 6 0 5 47 11 0.356 0.305 0.466 0.4 3 0.1 1 0.2 3 0.2 1 0.3 7 0.3 5 0.3 2 0.2 7 0.177 0.1 9 0.3 0.3 1 0.4 2 0.3 9 0.2 0.39
Average 4 2 5 7 1 1 2 45 2 85 50.201 0.17 5 0.3445 0.345 0.4415 0.4 4 0.1 8 0.1925 0.2 5 0.305 0.40 5 0.29 5 0. 9 0.188 0.1715 0.33 0.356 0.41 5 0.33 0.25 0.355
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PT 016 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.197 0.171 0.345 0.384 0.466 0.453 0.16 0.203 0.287 0.263 0.399 0.381 0.276 0.219 0.262 0.311 0.351 0.423 0.279 0.27 0.33
B 0.205 0.186 0.333 0.383 0.417 0.395 0.151 0.21 0.269 0.256 0.355 0.366 0.268 0.187 0.219 0.358 0.288 0.452 0.273 0.3 0.311
average 0.201 0.1785 0.339 0.3835 0.4415 0.424 0.1555 0.2065 0.278 0.2595 0.377 0.3735 0.272 0.203 0.2405 0.3345 0.3195 0.4375 0.276 0.285 0.3205
PT 017 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.187 0.186 0.239 0.287 0.381 0.309 0.101 0.182 0.217 0.259 0.302 0.357 0.234 0.199 0.214 0.2307 0.282 0.295 0.289 0.199 0.29
B 0.212 0.206 0.3 0.36 0.317 0.359 0.161 0.179 0.209 0.292 0.329 0.291 0.226 0.189 0.201 0.276 0.35 0.267 0.311 0.197 0.345
average 0 0.1995 0.196 0.2695 0.3235 0.349 0.334 0.131 0.1805 0.213 0.2755 0.3155 0.324 0.23 0.194 0.2075 0.2534 0.316 0.281 0.3 0.198 .3175
PT 018 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A  0.262 0.266 0.366 0.256 0.396 0.371 0.14 0.239 0.311 0.25 0.332 0.351 0.317 0.278 0.234 0.294 0.289 0.349 0.311 0.274 0.301
B 0.266 0.271 0.329 0.268 0.409 0.289 0.146 0.237 0.239 0.262 0.334 0.343 0.32 0.247 0.242 0.296 0.332 0.358 0.321 0.278 0.289
average 0.264 0.2685 0.3475 0.262 0.4025 0.33 0.143 0.238 0.275 0.256 0.333 0.347 0.3185 0.2625 0.238 0.295 0.3105 0.3535 0.316 0.276 0.295
IL2 PT 019 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.401 0.421 0.543 0.591 0.741 0.654 0.145 0.318 0.511 0.637 0.661 0.5 0.51 0.358 0.399 0.469 0.435 0.536 0.489 0.332 0.544
B 0.423 0.408 0.481 0.63 0.623 0.742 0.13 0.321 0.609 0.65 0.72 0.488 0.518 0.371 0.345 0.48 0.456 0.533 0.448 0.362 0.487
average 0.412 0.4145 0.512 0.6105 0.682 0.698 0.1375 0.3195 0.56 0.6435 0.6905 0.494 0.514 0.3645 0.372 0.4745 0.4455 0.5345 0.4685 0.347 0.5155
PT 020 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.409 0.494 0.499 0.7 0.773 0.766 0.118 0.393 0.498 0.442 0.535 0.5 0.57 0.402 0.476 0.424 0.445 0.667 0.444 0.275 0.455
B 0.55 0.453 0.545 0.648 0.776 0.722 0.111 0.344 0.566 0.479 0.487 0.581 0.51 0.467 0.356 0.566 0.522 0.567 0.459 0.189 0.437
average 0.4795 0.4735 0.522 0.674 0.7745 0.744 0.1145 0.3685 0.532 0.4605 0.511 0.5405 0.54 0.4345 0.416 0.495 0.4835 0.617 0.4515 0.232 0.446
PT 021 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.224 0.246 0.268 0.325 0.391 0.314 0.127 0.203 0.299 0.386 0.496 0.456 0.266 0.306 0.301 0.315 0.254 0.353 0.39 0.224 0.254
B 0.252 0.197 0.189 0.328 0.382 0.321 0.113 0.206 0.323 0.395 0.455 0.412 0.356 0.326 0.323 0.311 0.246 0.328 0.322 0.236 0.246
average 0.238 0.2215 0.2285 0.3265 0.3865 0.3175 0.12 0.2045 0.311 0.3905 0.4755 0.434 0.311 0.316 0.312 0.313 0.25 0.3405 0.356 0.23 0.25
PT 022 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.305 0.339 0.429 0.47 0.551 0.453 0.145 0.308 0.479 0.458 0.426 0.492 0.553 0.429 0.434 0.453 0.497 0.597 0.609 0.368 0.486
B 0.354 0.398 0.456 0.437 0.489 0.429 0.152 0.281 0.458 0.406 0.511 0.511 0.489 0.387 0.401 0.489 0.223 0.697 0.662 0.285 0.505
average 0.3295 0.3685 0.4425 0.4535 0.52 0.441 0.1485 0.2945 0.4685 0.432 0.4685 0.5015 0.521 0.408 0.4175 0.471 0.36 0.647 0.6355 0.3265 0.4955
PT 023 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.396 0.349 0.567 0.612 0.703 0.641 0.27 0.336 0.689 0.784 0.884 0.789 0.621 0.673 0.501 0.621 0.599 0.749 0.682 0.521 0.65
B 0.384 0.331 0.499 0.749 0.812 0.688 0.266 0.322 0.738 0.772 0.813 0.851 0.655 0.553 0.49 0.602 0.681 0.694 0.588 0.506 0.624
average 0.39 0.34 0.533 0.6805 0.7575 0.6645 0.268 0.329 0.7135 0.778 0.8485 0.82 0.638 0.613 0.4955 0.6115 0.64 0.7215 0.635 0.5135 0.637
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PT 024 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.589 0.654 0.809 1.08 1.262 0.999 0.306 0.661 0.844 0.88 0.936 0.954 0.875 0.475 0.689 0.861 0.796 0.972 0.892 0.73 0.747
B 0.607 0.584 0.79 0.947 1.088 0.944 0.262 0.616 0.819 0.728 0.871 0.904 0.799 0.52 0.538 0.819 1.02 1.106 0.827 0.745 0.822
average 0.598 0.619 0.7995 1.0135 1.175 0.9715 0.284 0.6385 0.8315 0.804 0.9035 0.929 0.837 0.4975 0.6135 0.84 0.908 1.039 0.8595 0.7375 0.7845
PT 025 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.278 0.251 0.3778 0.399 0.57 0.474 0.192 0.211 0.301 0.297 0.684 0.552 0.377 0.494 0.299 0.438 0.488 0.666 0.459 0.487 0.502
B 0.296 0.226 0.345 0.467 0.577 0.476 0.156 0.2 0.372 0.349 0.599 0.548 0.396 0.452 0.32 0.436 0.5 0.615 0.389 0.333 0.504
average 0.287 0.2385 0.3614 0.433 0.5735 0.475 0.174 0.2055 0.3365 0.323 0.6415 0.55 0.3865 0.473 0.3095 0.437 0.494 0.6405 0.424 0.41 0.503
PT 026 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.255 0.397 0.389 0.273 0.414 0.419 0.167 0.217 0.282 0.273 0.325 0.367 0.358 0.189 0.189 0.36 0.371 0.399 0.388 0.336 0.367
B 0.26 0.293 0.278 0.283 0.432 0.352 0.112 0.173 0.279 0.273 0.359 0.371 0.32 0.256 0.297 0.381 0.339 0.381 0.41 0.388 0.346
average 0.2575 0.345 0.3335 0.278 0.423 0.3855 0.1395 0.195 0.2805 0.273 0.342 0.369 0.339 0.2225 0.243 0.3705 0.355 0.39 0.399 0.362 0.3565
PT 027 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
A. 0.219 0.273 0.379 0.349 0.545 0.469 0.108 0.248 0.408 0.297 0.373 0.301 0.298 0.292 0.231 0.389 0.307 0.426 0.318 0.273 0.302
B 0.257 0.263 0.347 0.421 0.399 0.478 0.118 0.293 0.435 0.336 0.463 0.328 0.252 0.312 0.176 0.328 0.297 0.435 0.263 0.202 0.31
average 0.238 0.268 0.363 0.385 0.472 0.4735 0.113 0.2705 0.4215 0.3165 0.418 0.3145 0.275 0.302 0.2035 0.3585 0.302 0.4305 0.2905 0.2375 0.306
PT 028 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
 0.167 0.199 0.48 0.459 0.68 0.579 0.158 0.172 0.359 0.368 0.513 0.538 0.369 0.262 0.272 0.455 0.384 0.471 0.366 0.259 0.305
 0.241 0.184 0.468 0.344 0.648 0.584 0.167 0.186 0.392 0.367 0.527 0.468 0.398 0.269 0.279 0.414 0.415 0.544 0.362 0.274 0.361
average 0.204 0.1915 0.474 0.4015 0.664 0.5815 0.1625 0.179 0.3755 0.3675 0.52 0.503 0.3835 0.2655 0.2755 0.4345 0.3995 0.5075 0.364 0.2665 0.333
PT 029 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
 0.18 0.192 0.347 0.354 0.339 0.29 0.178 0.185 0.275 0.228 0.255 0.284 0.249 0.277 0.307 0.252 0.271 0.289 0.234 0.196 0.231
 0.201 0.183 0.3 0.379 0.462 0.27 0.135 0.173 0.254 0.188 0.226 0.282 0.201 0.226 0.211 0.244 0.32 0.322 0.254 0.2 0.264
average 0.1905 0.1875 0.3235 0.3665 0.4005 0.28 0.1565 0.179 0.2645 0.208 0.2405 0.283 0.225 0.2515 0.259 0.248 0.2955 0.3055 0.244 0.198 0.2475
PT 030 Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
 0.238 0.302 0.342 0.488 0.428 0.519 0.176 0.218 0.401 0.358 0.578 0.468 0.44 0.351 0.288 0.395 0.396 0.482 0.433 0.288 0.441
 0.208 0.283 0.348 0.417 0.479 0.471 0.145 0.238 0.42 0.344 0.61 0.363 0.404 0.38 0.372 0.343 0.315 0.448 0.476 0.311 0.472
average 0.223 0.2925 0.345 0.4525 0.4535 0.495 0.1605 0.228 0.4105 0.351 0.594 0.4155 0.422 0.3655 0.33 0.369 0.3555 0.465 0.4545 0.2995 0.4565
overall Control IL10P IL7P IL6P IL2P INP M IL10 IL7 IL6 IL2 IL2,7 POKE IL6,10 IL7,10 IL2,6 GMCSFP INTER IL6,7 IL2,10 GMCSF
Total Ave 0.5194 0.517 0.617 0.6617 0.7205 0.6877 0.3081 0.4783 0.616 0.6276 0.6956 0.6495 0.607 0.5355 0.516 0.6278 0.6068 0.7277 0.6396 0.5538 0.6236
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 Graph 8.1 : Absorbance results for proliferation Assay of B-CLL cells in response to cytokines and growth factors with background
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Appendix II: B-CLL Cell Survival results based on the morphological changes. 
 
Table 8.2 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on addition of IL-2 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 288 252 217 112 148 183 400 400 400 72 63 54.25 
2 269 253 255 131 147 145 400 400 400 67.25 63.25 63.75 
3 317 257 216 83 143 184 400 400 400 79.25 64.25 54 
4 332 291 297 68 109 103 400 400 400 83 72.75 74.25 
5 279 277 258 121 123 142 400 400 400 69.75 69.25 64.5 
6 271 249 248 129 151 152 400 400 400 67.75 62.25 62 
7 280 238 246 120 162 154 400 400 400 70 59.5 61.5 
8 333 289 258 67 111 142 400 400 400 83.25 72.25 64.5 
9 327 273 257 73 127 143 400 400 400 81.75 68.25 64.25 
10 282 277 239 118 123 161 400 400 400 70.5 69.25 59.75 
11 245 223 216 155 177 184 400 400 400 61.25 55.75 54 
13 282 244 217 118 156 183 400 400 400 70.5 61 54.25 
14 292 252 215 108 148 185 400 400 400 73 63 53.75 
15 297 256 213 103 144 187 400 400 400 74.25 64 53.25 
16 256 239 215 144 161 185 400 400 400 64 59.75 53.75 
17 302 261 210 98 139 190 400 400 400 75.5 65.25 52.5 
18 289 244 213 111 156 187 400 400 400 72.25 61 53.25 
19 291 237 211 109 163 189 400 400 400 72.75 59.25 52.75 
20 255 236 212 145 164 188 400 400 400 63.75 59 53 
21 269 217 213 131 183 187 400 400 400 67.25 54.25 53.25 
22 284 254 177 116 146 223 400 400 400 71 63.5 44.25 
23 266 217 289 134 183 111 400 400 400 66.5 54.25 72.25 
24 288 232 214 112 168 186 400 400 400 72 58 53.5 
25 274 216 253 126 184 147 400 400 400 68.5 54 63.25 
26 294 255 254 106 145 146 400 400 400 73.5 63.75 63.5 
Mean 286.48 249.56 232.52 113.52 150.44 167.48 400 400 400 71.62 62.39 58.13 
Median 284 252 217 116 148 183 400 400 400 71 63 54.25 
SD 22.8129 20.9545 27.9108 22.8129 20.95447 27.91075 0 0 0 5.703215 5.238619 6.9777 
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 Table 8.3 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on addition of IL-6 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 238 208 216 162 192 184 400 400 400 59.5 52 54 
2 205 241 217 195 159 183 400 400 400 51.25 60.25 54.25 
3 222 204 176 178 196 224 400 400 400 55.5 51 44 
4 201 170 173 199 230 227 400 400 400 50.25 42.5 43.25 
5 209 174 172 191 226 228 400 400 400 52.25 43.5 43 
6 242 176 210 158 224 190 400 400 400 60.5 44 52.5 
7 288 252 279 112 148 121 400 400 400 72 63 69.75 
8 255 239 216 145 161 184 400 400 400 63.75 59.75 54 
9 214 189 171 186 211 229 400 400 400 53.5 47.25 42.75 
10 250 211 173 150 189 227 400 400 400 62.5 52.75 43.25 
11 295 255 242 105 145 158 400 400 400 73.75 63.75 60.5 
13 204 174 176 196 226 224 400 400 400 51 43.5 44 
14 252 215 172 148 185 228 400 400 400 63 53.75 43 
15 216 177 210 184 223 190 400 400 400 54 44.25 52.5 
16 214 169 172 186 231 228 400 400 400 53.5 42.25 43 
17 251 244 209 149 156 191 400 400 400 62.75 61 52.25 
18 243 211 168 157 189 232 400 400 400 60.75 52.75 42 
19 213 200 177 187 200 223 400 400 400 53.25 50 44.25 
20 215 198 211 185 202 189 400 400 400 53.75 49.5 52.75 
21 246 189 210 154 211 190 400 400 400 61.5 47.25 52.5 
22 213 175 162 187 225 238 400 400 400 53.25 43.75 40.5 
23 286 215 211 114 185 189 400 400 400 71.5 53.75 52.75 
24 214 210 212 186 190 188 400 400 400 53.5 52.5 53 
25 261 249 244 139 151 156 400 400 400 65.25 62.25 61 
26 236 210 171 164 190 229 400 400 400 59 52.5 42.75 
Mean 235.32 206.2 198 164.68 193.8 202 400 400 400 58.83 51.55 49.5 
Median 236 208 209 164 192 191 400 400 400 59 52 52.25 
SD .927.3948 27.7399 29.6156 27.3948 27.73986 29.61559 0 0 0 6.848707 6 34966 7.4039 
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Table 8.4 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on addition of IL-7 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 202 134 129 198 266 271 400 400 400 50.5 33.5 32.25 
2 240 203 175 160 197 225 400 400 400 60 50.75 43.75 
3 215 135 133 185 265 267 400 400 400 53.75 33.75 33.25 
4 176 129 119 224 271 281 400 400 400 44 32.25 29.75 
5 217 203 171 183 197 229 400 400 400 54.25 50.75 42.75 
6 210 171 162 190 229 238 400 400 400 52.5 42.75 40.5 
7 173 163 155 227 237 245 400 400 400 43.25 40.75 38.75 
8 212 168 156 188 232 244 400 400 400 53 42 39 
9 174 159 134 226 241 266 400 400 400 43.5 39.75 33.5 
10 210 164 150 190 236 250 400 400 400 52.5 41 37.5 
11 189 129 128 211 271 272 400 400 400 47.25 32.25 32 
13 179 132 124 221 268 276 400 400 400 44.75 33 31 
14 210 199 173 190 201 227 400 400 400 52.5 49.75 43.25 
15 198 170 172 202 230 228 400 400 400 49.5 42.5 43 
16 174 166 136 226 234 264 400 400 400 43.5 41.5 34 
17 200 174 169 200 226 231 400 400 400 50 43.5 42.25 
18 209 173 170 191 227 230 400 400 400 52.25 43.25 42.5 
19 159 133 130 241 267 270 400 400 400 39.75 33.25 32.5 
20 163 131 125 237 269 275 400 400 400 40.75 32.75 31.25 
21 189 134 133 211 266 267 400 400 400 47.25 33.5 33.25 
22 173 161 135 227 239 265 400 400 400 43.25 40.25 33.75 
23 193 176 155 207 224 245 400 400 400 48.25 44 38.75 
24 175 168 155 225 232 245 400 400 400 43.75 42 38.75 
25   2  33.5  161 134 120 239 266 80 400 400 400 40.25 30
26 43.25 40.75 207 173 163 193 227 237 400 400 400 51.75 
Mean 192.32 159.28 146.88 207.68 240.72 253.12 400 400 400 48.08 39.82 36.72 
Median 193 164 150 207 236 250 400 400 400 48.25 41 37.5 
SD 20.9518 23.5735 19.1079 20.9518 23.5735 19.10785 0 0 0 5.237943 5.893376 4.777 
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 Table 8.5 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on addition of IL-10 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 185 96 99 215 304 301 400 400 400 46.25 24 24.75 
2 156 94 67 244 306 333 400 400 400 39 23.5 16.75 
3 159 90 69 241 310 331 400 400 400 39.75 22.5 17.25 
4 150 105 35 250 295 365 400 400 400 37.5 26.25 8.75 
5 133 92 31 267 308 369 400 400 400 33.25 23 7.75 
6 188 132 66 212 268 334 400 400 400 47 33 16.5 
7 151 94 58 249 306 342 400 400 400 37.75 23.5 14.5 
8 174 91 66 226 309 334 400 400 400 43.5 22.75 16.5 
9 174 159 102 226 241 298 400 400 400 43.5 39.75 25.5 
10 129 65 26 271 335 374 400 400 400 32.25 16.25 6.5 
11 188 129 70 212 271 330 400 400 400 47 32.25 17.5 
13 165 90 101 235 310 299 400 400 400 41.25 22.5 25.25 
14 135 96 30 265 304 370 400 400 400 33.75 24 7.5 
15 126 85 29 274 315 371 400 400 400 31.5 21.25 7.25 
16 180 122 62 220 278 338 400 400 400 45 30.5 15.5 
17 150 83 29 250 317 371 400 400 400 37.5 20.75 7.25 
18 126 81 26 274 319 374 400 400 400 31.5 20.25 6.5 
19 130 77 24 270 323 376 400 400 400 32.5 19.25 6 
20 125 45 21 275 355 379 400 400 400 31.25 11.25 5.25 
21 151 89 100 249 311 300 400 400 400 37.75 22.25 25 
22 122 78 22 278 322 378 400 400 400 30.5 19.5 5.5 
23 131 83 28 269 317 372 400 400 400 32.75 20.75 7 
24 175 133 62 225 267 338 400 400 400 43.75 33.25 15.5 
25 161 80 62 239 320 338 400 400 400 40.25 20 15.5 
26 160 77 65 240 323 335 400 400 400 40 19.25 16.25 
Mean 152.96 94.64 54 247.04 305.36 346 400 400 400 38.24 23.66 13.5 
Median 151 90 62 249 310 338 400 400 400 37.75 22.5 15.5 
SD 21.8069 24.2828 27.3054 21.8069 24.28285 27.30537 0 0 0 5.45172 6.070712 6.8263 
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Table 8.6 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on addition of IFN 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 352 322 281 48 78 119 400 400 400 88 80.5 70.25 
2 334 291 277 66 109 123 400 400 400 83.5 72.75 69.25 
3 312 254 241 88 146 159 400 400 400 78 63.5 60.25 
4 256 275 251 144 125 149 400 400 400 64 68.75 62.75 
5 333 292 273 67 108 127 400 400 400 83.25 73 68.25 
6 336 294 289 64 106 111 400 400 400 84 73.5 72.25 
7 335 324 308 65 76 92 400 400 400 83.75 81 77 
8 330 281 271 70 119 129 400 400 400 82.5 70.25 67.75 
9 311 255 224 89 145 176 400 400 400 77.75 63.75 56 
10 325 295 240 75 105 160 400 400 400 81.25 73.75 60 
11 293 286 252 107 114 148 400 400 400 73.25 71.5 63 
13 278 245 229 122 155 171 400 400 400 69.5 61.25 57.25 
14 329 294 246 71 106 154 400 400 400 82.25 73.5 61.5 
15 368 322 295 32 78 105 400 400 400 92 80.5 73.75 
16 323 254 222 77 146 178 400 400 400 80.75 63.5 55.5 
17 331 291 248 69 109 152 400 400 400 82.75 72.75 62 
18 292 253 250 108 147 150 400 400 400 73 63.25 62.5 
19 368 336 331 32 64 69 400 400 400 92 84 82.75 
20 375 364 330 25 36 70 400 400 400 93.75 91 82.5 
21 332 255 242 68 145 158 400 400 400 83 63.75 60.5 
22 335 323 293 65 77 107 400 400 400 83.75 80.75 73.25 
23 293 276  107 124 112 400 400 400 73.25 69 72 288
24 330 286 283 70 114 117 400 400 400 82.5 71.5 70.75 
25 289 249 236 111 151 164 400 400 400 72.25 62.25 59 
26 365 344 294 35 56 106 400 400 400 91.25 86 73.5 
Mean 325 290.44 267.76 75 109.56 132.24 400 400 400 81.25 72.61 66.94 
Median 330 291 271 70 109 129 400 400 400 82.5 72.75 67.75 
SD 29.5212 32.6025 31.1786 29.5212 32.60251 31.17863 0 0 0 7.380295 8.150626 7.7947 
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 Table 8.7 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on addition of GM-CSF 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 249 233 175 151 167 225 400 400 400 62.25 58.25 43.75 
2 204 172 136 196 228 264 400 400 400 51 43 34 
3 240 209 173 160 191 227 400 400 400 60 52.25 43.25 
4 238 189 137 162 211 263 400 400 400 59.5 47.25 34.25 
5 285 215 176 115 185 224 400 400 400 71.25 53.75 44 
6 252 224 169 148 176 231 400 400 400 63 56 42.25 
7 277 210 172 123 190 228 400 400 400 69.25 52.5 43 
8 291 273 250 109 127 150 400 400 400 72.75 68.25 62.5 
9 213 188 157 187 212 243 400 400 400 53.25 47 39.25 
10 212 193 169 188 207 231 400 400 400 53 48.25 42.25 
11 250 241 172 150 159 228 400 400 400 62.5 60.25 43 
13 245 229 211 155 171 189 400 400 400 61.25 57.25 52.75 
14 284 271 216 116 129 184 400 400 400 71 67.75 54 
15 244 215 210 156 185 190 400 400 400 61 53.75 52.5 
16 212 189 173 188 211 227 400 400 400 53 47.25 43.25 
17 210 188 166 190 212 234 400 400 400 52.5 47 41.5 
18 208 175 165 192 225 235 400 400 400 52 43.75 41.25 
19 277 250 242 123 150 158 400 400 400 69.25 62.5 60.5 
20 253 244 216 147 156 184 400 400 400 63.25 61 54 
21 245 229 137 155 171 263 400 400 400 61.25 57.25 34.25 
22 253 241 211 147 159 189 400 400 400 63.25 60.25 52.75 
23 250 277 249 150 123 151 400 400 400 62.5 69.25 62.25 
24 291 270 247 109 130 153 400 400 400 72.75 67.5 61.75 
25 279 231 215 121 169 185 400 400 400 69.75 57.75 53.75 
26 255 214 205 145 186 195 400 400 400 63.75 53.5 51.25 
Mean 248.68 222.8 189.96 151.32 177.2 210.04 400 400 400 62.17 55.7 47.49 
Median 250 224 175 150 176 225 400 400 400 62.5 56 43.75 
SD 27.4723 31.0403 35.2792 27.4723 31.0403 35.27922 0 0 0 6.868072 7.760074 8.8198 
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Table 8.8 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on addition of PWM 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 189 135 117 211 265 283 400 400 400 47.25 33.75 29.25 
2 210 175 156 190 225 244 400 400 400 52.5 43.75 39 
3 172 133 121 228 267 279 400 400 400 43 33.25 30.25 
4 209 170 192 191 230 208 400 400 400 52.25 42.5 48 
5 172 160 155 228 240 245 400 400 400 43 40 38.75 
6 179 161 152 221 239 248 400 400 400 44.75 40.25 38 
7 186 161 123 214 239 277 400 400 400 46.5 40.25 30.75 
8 249 215 210 151 185 190 400 400 400 62.25 53.75 52.5 
9 211 202 188 189 198 212 400 400 400 52.75 50.5 47 
10 171 166 134 229 234 266 400 400 400 42.75 41.5 33.5 
11 209 201 190 191 199 210 400 400 400 52.25 50.25 47.5 
13 212 199 123 188 201 277 400 400 400 53 49.75 30.75 
14 201 190 134 199 210 266 400 400 400 50.25 47.5 33.5 
15 212 166 123 188 234 277 400 400 400 53 41.5 30.75 
16 177 168 152 223 232 248 400 400 400 44.25 42 38 
17 170 175 190 230 225 210 400 400 400 42.5 43.75 47.5 
18 252 211 189 148 189 211 400 400 400 63 52.75 47.25 
19 200 172 155 200 228 245 400 400 400 50 43 38.75 
20 176 215 186 224 185 214 400 400 400 44 53.75 46.5 
21 209 173 149 191 227 251 400 400 400 52.25 43.25 37.25 
22 199 165 127 201 235 273 400 400 400 49.75 41.25 31.75 
23 174 166 163 226 234 237 400 400 400 43.5 41.5 40.75 
24 211 198 188 189 202 212 400 400 400 52.75 49.5 47 
25 215 170 161 185 230 239 400 400 400 53.75 42.5 40.25 
26 216 150 215 184 250 185 400 400 400 54 37.5 53.75 
Mean 199.24 175.88 159.72 200.76 224.12 240.28 400 400 400 49.81 43.97 39.93 
Median 201 170 155 199 230 245 400 400 400 50.25 42.5 38.75 
SD 22.6335 22.6133 30.0521 22.6335 22.61327 30.05207 0 0 0 5.658364 5.653318 7.513 
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Table 8.9 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on addition of Control 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 210 199 119 190 201 281 400 400 400 52.5 49.75 29.75 
2 173 149 129 227 251 271 400 400 400 43.25 37.25 32.25 
3 209 159 124 191 241 276 400 400 400 52.25 39.75 31 
4 209 170 156 191 230 244 400 400 400 52.25 42.5 39 
5 214 192 130 186 208 270 400 400 400 53.5 48 32.5 
6 211 197 126 189 203 274 400 400 400 52.75 49.25 31.5 
7 171 163 150 229 237 250 400 400 400 42.75 40.75 37.5 
8 169 188 133 231 212 267 400 400 400 42.25 47 33.25 
9 213 200 167 187 200 233 400 400 400 53.25 50 41.75 
10 216 230 211 184 170 189 400 400 400 54 57.5 52.75 
11 210 159 127 190 241 273 400 400 400 52.5 39.75 31.75 
13 205 196 132 195 204 268 400 400 400 51.25 49 33 
14 204 192 134 196 208 266 400 400 400 51 48 33.5 
15 210 125 95 190 275 305 400 400 400 52.5 31.25 23.75 
16 206 231 200 194 169 200 400 400 400 51.5 57.75 50 
17 202 170 129 198 230 271 400 400 400 50.5 42.5 32.25 
18 231 158 97 169 242 303 400 400 400 57.75 39.5 24.25 
19 200 150 155 200 250 245 400 400 400 50 37.5 38.75 
20 209 166 127 191 234 273 400 400 400 52.25 41.5 31.75 
21 213 206 189 187 194 211 400 400 400 53.25 51.5 47.25 
22 244 201 128 156 199 272 400 400 400 61 50.25 32 
23 177 120 112 223 280 288 400 400 400 44.25 30 28 
24 214 241 170 186 159 230 400 400 400 53.5 60.25 42.5 
25 208 152 133 192 248 267 400 400 400 52 38 33.25 
26 214 121 126 186 279 274 400 400 400 53.5 30.25 31.5 
Mean 205.68 177.4 139.96 194.32 222.6 260.04 400 400 400 51.42 44.35 34.99 
Median 209 170 130 191 230 270 400 400 400 52.25 42.5 32.5 
SD 2 817.2499 33.0593 28.8826 17.2499 33.05929 8.88264 0 0 0 4.312482 .264823 7.2207 
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Table 8.10 Results of the B-CLL survival counted at day 1 to day 5 and percentage survival on  B-CLL cells cultured $ 
4 degrees without cytokines 
             
  Number of S cells Number of A cells Total % of Survival 
PT No D1 D3 D5 D1 D3 D5 D1 D3 D5 D1 D3 D5 
1 252 231 205 148 169 195 400 400 400 63 57.75 51.25 
2 249 203 157 151 197 243 400 400 400 62.25 50.75 39.25 
3 289 280 253 111 120 147 400 400 400 72.25 70 63.25 
4 245 211 191 155 189 209 400 400 400 61.25 52.75 47.75 
5 253 251 244 147 149 156 400 400 400 63.25 62.75 61 
6 250 249 241 150 151 159 400 400 400 62.5 62.25 60.25 
7 253 244 246 147 156 154 400 400 400 63.25 61 61.5 
8 213 208 199 187 192 201 400 400 400 53.25 52 49.75 
9 251 243 230 149 157 170 400 400 400 62.75 60.75 57.5 
10 253 245 198 147 155 202 400 400 400 63.25 61.25 49.5 
11 239 211 216 161 189 184 400 400 400 59.75 52.75 54 
13 257 245 203 143 155 197 400 400 400 64.25 61.25 50.75 
14 215 211 197 185 189 203 400 400 400 53.75 52.75 49.25 
15 255 243 213 145 157 187 400 400 400 63.75 60.75 53.25 
16 215 211 168 185 189 232 400 400 400 53.75 52.75 42 
17 217 248 210 183 152 190 400 400 400 54.25 62 52.5 
18 255 212 169 145 188 231 400 400 400 63.75 53 42.25 
19 209 209 167 191 191 233 400 400 400 52.25 52.25 41.75 
20 212 251 199 188 149 201 400 400 400 53 62.75 49.75 
21 213 200 176 187 200 224 400 400 400 53.25 50 44 
22 255 241 236 145 159 164 400 400 400 63.75 60.25 59 
23 216 211 166 184 189 234 400 400 400 54 52.75 41.5 
24 256 239 214 144 161 186 400 400 400 64 59.75 53.5 
25 215 216 173 185 184 227 400 400 400 53.75 54 43.25 
26 214 210 199 186 190 201 400 400 400 53.5 52.5 49.75 
Mean 238.04 228.92 202.8 161.96 171.08 197.2 400 400 400 59.51 57.23 50.7 
Median 249 231 199 151 169 201 400 400 400 62.25 57.75 49.75 
SD 21.7591 20.9203 27.9717 21.7591 20.92033 27.97171 0 0 0 5.439765 5.230081 6.9929 
 Appendix III: The ANOVA procedure and Bonferroni (Dunn) t Test results 
comparing the difference in survival at day 5 on B-CLL cells treated with 
different mitogen.  
 
Difference in Survival at  Day 5 on treatment of B-CLL cells cultured with 
different mitogens 
 
The ANOVA Procedure 
Class Level Information 
Class Levels Values 
GF 8 CONTROL GM-CSF IFN IL-10 IL-2 IL-6 IL-7 PWM 
 
Number of Observations Read 200
Number of Observations Used 200
 
Dependent Variable: Day 1 
Source DF Sum of 
Squares 
Mean 
Square 
F 
Value 
Pr > F 
Model 7 33563.72875 4794.81839 132.80 <.0001
Error 192 6932.22000 36.10531     
Corrected 
Total 
199 40495.94875       
 
R-Square Coeff Var Root MSE Day 1 Mean 
0.828817 10.41787 6.008770 57.67750 
 
Source DF Anova SS Mean Square F Value Pr > F 
GF 7 33563.72875 4794.81839 132.80 <.0001 
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 The ANOVA Procedure 
  
Dependent Variable: Day 3 
Source DF Sum of 
Squares 
Mean 
Square 
F 
Value 
Pr > F 
Model 7 39022.56969 5574.65281 119.23 <.0001
Error 192 8976.98500 46.75513     
Corrected 
Total 
199 47999.55469       
 
R-Square Coeff Var Root MSE Day 3 Mean 
0.812978 13.88204 6.837772 49.25625 
 
Source DF Anova SS Mean Square F Value Pr > F 
GF 7 39022.56969 5574.65281 119.23 <.0001 
 
Dependent Variable: Day 5 
Source DF Sum of 
Squares 
Mean 
Square 
F 
Value 
Pr > F 
Model 7 46161.10000 6594.44286 125.59 <.0001
Error 192 10081.27500 52.50664     
Corrected 
Total 
199 56242.37500       
 
R-Square Coeff Var Root MSE Day 5 Mean 
0.820753 16.69619 7.246147 43.40000 
 
Source DF Anova SS Mean Square F Value Pr > F 
GF 7 46161.10000 6594.44286 125.59 <.0001 
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 The ANOVA Procedure: Bonferroni (Dunn) t Tests at Day 1 
Note: This test controls the Type I experimentwise error rate, but it generally 
has a higher Type II error rate than REGWQ. 
Alpha 0.05 
Error Degrees of Freedom 192 
Error Mean Square 36.10531
Critical Value of t 3.16806 
Minimum Significant Difference 5.3842 
 
Means with the same letter are 
not significantly different. 
Bon Grouping Mean N GF 
A 81.250 25 IFN 
        
B 71.620 25 IL-2 
        
C 62.170 25 GM-CSF 
C       
C 58.830 25 IL-6 
        
D 51.420 25 CONTRO
D       
D 49.810 25 PWM 
D       
D 48.080 25 IL-7 
        
E 38.240 25 IL-10 
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The ANOVA Procedure : Bonferroni (Dunn) t Tests at Day 3 
Note: This test controls the Type I experimentwise error rate, but it generally 
has a higher Type II error rate than REGWQ. 
Alpha 0.05 
Error Degrees of Freedom 192 
Error Mean Square 46.75513
Critical Value of t 3.16806 
Minimum Significant Difference 6.1271 
 
Means with the same letter are 
not significantly different. 
Bon Grouping Mean N GF 
A 72.610 25 IFN 
        
B 62.390 25 IL-2 
        
C 55.700 25 GM-CSF 
C       
C 51.550 25 IL-6 
        
D 44.350 25 CONTRO
D       
D 43.970 25 PWM 
D       
D 39.820 25 IL-7 
        
E 23.660 25 IL-10 
 
MS Seahloli – MEDC 801 MSC (Med) 20 December 2005 amended 6 June 2006 
Student No 9708297R 
 
Page 117 of 123
  
The ANOVA Procedure : Bonferroni (Dunn) t Tests at Day 5 
Note: This test controls the Type I experimentwise error rate, but it generally 
has a higher Type II error rate than REGWQ. 
Alpha 0.05 
Error Degrees of Freedom 192 
Error Mean Square 52.50664
Critical Value of t 3.16806 
Minimum Significant Difference 6.493 
 
Means with the same letter are 
not significantly different. 
Bon Grouping Mean N GF 
A 66.940 25 IFN 
        
B 58.130 25 IL-2 
        
C 49.500 25 IL-6 
C       
C 47.490 25 GM-CSF 
        
D 39.930 25 PWM 
D       
D 36.720 25 IL-7 
D       
D 34.990 25 CONTRO
        
E 13.500 25 IL-10 
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 Difference in Survival at Day 5 on B-CLL cells  treated with different 
mitogens 
  
Means and Descriptive Statistics 
 
GF Mean of 
Day 1 
Mean of 
Day 3 
Mean 
of Day 
5 
Std. Dev. 
of Day 1 
Std. 
Dev. of 
Day 3 
Std. 
Dev. of 
Day 5 
  57.6775 49.2563 43.40 14.2652 15.5307 16.8115 
CONTRO 51.4200 44.3500 34.99 4.3125 8.2648 7.2207 
GM-CSF 62.1700 55.7000 47.49 6.8681 7.7601 8.8198 
IFN 81.2500 72.6100 66.94 7.3803 8.1506 7.7947 
IL-10 38.2400 23.6600 13.50 5.4517 6.0707 6.8263 
IL-2 71.6200 62.3900 58.13 5.7032 5.2386 6.9777 
IL-6 58.8300 51.5500 49.50 6.8487 6.9350 7.4039 
IL-7 48.0800 39.8200 36.72 5.2379 5.8934 4.7770 
PWM 49.8100 43.9700 39.93 5.6584 5.6533 7.5130 
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Difference in Survival at  Day 1 on B_CLL cells treated  with different 
mitogens 
  
Means Plot of Day 1 by GF 
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Difference in Survival at Day 3 on B-CLL cells treated with different 
mitogens 
  
Means Plot of Day 3 by GF 
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Difference in Survival at  Day 5 on B-CLL cells treated with different 
mitogens 
  
Means Plot of Day 5 by GF 
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APPENDIX IV:  
 
The University of the Witwatersrand, Johannesburg, Committee for 
Research on Human Subjects (Medical) Clearance Certificate for Protocol 
Number 00/05/24 
 
